CN117751113A - Aromatic acetylene derivative and preparation method and application thereof - Google Patents

Aromatic acetylene derivative and preparation method and application thereof Download PDF

Info

Publication number
CN117751113A
CN117751113A CN202280052824.6A CN202280052824A CN117751113A CN 117751113 A CN117751113 A CN 117751113A CN 202280052824 A CN202280052824 A CN 202280052824A CN 117751113 A CN117751113 A CN 117751113A
Authority
CN
China
Prior art keywords
phenyl
methyl
ethynyl
pyrimidin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280052824.6A
Other languages
Chinese (zh)
Inventor
郭阳辉
王鑫
曹琪
孟力陈
吴诺毅
邬澄飞
陈友喜
叶成
钱文建
陈磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Hisun Pharmaceutical Co Ltd
Shanghai Aryl Pharmtech Co Ltd
Original Assignee
Zhejiang Hisun Pharmaceutical Co Ltd
Shanghai Aryl Pharmtech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Hisun Pharmaceutical Co Ltd, Shanghai Aryl Pharmtech Co Ltd filed Critical Zhejiang Hisun Pharmaceutical Co Ltd
Publication of CN117751113A publication Critical patent/CN117751113A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to an aromatic acetylene derivative, a preparation method thereof and application of a pharmaceutical composition containing the derivative in medicine. In particular, the invention relates to an aromatic acetylene derivative shown in a general formula (I), a preparation method and pharmaceutically acceptable salts thereof, and application thereof as a therapeutic agent, in particular to an LPXC inhibitor, wherein each substituent in the general formula (I) is defined as the specification.

Description

Aromatic acetylene derivative and preparation method and application thereof
The present application claims priority from the following chinese patent applications: 1) The aromatic acetylene derivatives are submitted to China national intellectual property agency, application number 202110893756.3 and Chinese patent application with the name of aromatic acetylene derivatives, preparation method and application thereof in 2021, 8 and 5 days; 2) The aromatic acetylene derivatives are submitted to China national intellectual property agency, application number 202210596714.8 and Chinese patent application with the name of aromatic acetylene derivatives, preparation method and application thereof in 2022 and 5-30 days; 3) The aromatic acetylene derivatives and the preparation method and the application thereof are submitted to China national intellectual property agency, application number 202210756227.3 and Chinese patent application with the name of aromatic acetylene derivatives and the application of aromatic acetylene derivatives at the year of 2022 and the month of 6 and 29. The entire contents of the above-mentioned chinese patent application are incorporated herein by reference.
Technical Field
The invention relates to an aromatic acetylene derivative, a preparation method thereof, a pharmaceutical composition containing the aromatic acetylene derivative and application of the aromatic acetylene derivative or the pharmaceutical composition as a therapeutic agent, in particular as an LPXC inhibitor.
Background
The thirty to sixty decades of the twentieth century are the golden period for the development of antibiotics, which are widely used worldwide, but bacterial resistance problems also continue to occur, and resistant bacteria have become a major problem threatening human health. The multi-drug resistant gram-negative bacteria is one of the main pathogens causing infection, and the drugs for treating the multi-drug resistant gram-negative bacteria infection are seriously deficient in clinic at present, and the drugs with higher toxicity are still adopted. In recent years, bacterial resistance has been a hot topic in the international medical community, but development speed is slow, and few compounds enter clinical researches at home and abroad, so finding a novel gram-negative bacterial antibacterial drug is an important problem to be solved urgently.
UDP-3-O- (R-3-hydroxymyristoyl) -N-acetylglucosamine deacetylase (LPXC) is a Zn-dependent enzyme 2+ Is the first rate limiting enzyme for the synthesis of lipid a, which is an important component of the outer membrane of gram-negative bacteria, and can anchor lipopolysaccharide to the outer membrane of cells, maintaining the integrity of cells themselves. Meanwhile, the antibacterial agent serves as a hydrophobic external barrier to prevent external factors such as antibiotics and the like from entering cells and protect bacteria from invasion. In addition, lipid A is also in bacteria The active ingredients of toxins, which are introduced into the blood through the intestinal mucosa, activate the immune response in humans and even cause severe septic shock, are also responsible for pathogenic infections caused by gram-negative bacteria. Thus, inhibition of LPXC can inhibit biosynthesis of lipid a of gram-negative bacteria, thereby effectively controlling infection with gram-negative bacteria.
At present, the further cognition of the structure and the characteristics of the LPXC is mostly obtained by separating, purifying and analyzing and identifying LPXC crystals of escherichia coli, pseudomonas aeruginosa and hyperthermophilic bacteria. The LPXC structures from these three different sources are highly similar and all contain two domains with the active region at the junction of the 2 domains. Each domain comprises an alpha helix and a beta sheet, which encloses the alpha helix, forming a sandwich of "beta-alpha-beta". The amino acid sequences of these two domains are slightly different, but have the same spatial structure. In addition, each domain has an insertion region corresponding thereto, which is formed by the beta sheet, forming a different functional region. Studies have shown that LPXC has high homology in gram-negative bacteria, has no common sequence with various enzyme systems of mammals, and from the biological point of view, inhibition of LPXC will be an ideal direction for studying antibacterial drugs due to its unique advantages of broad spectrum and low toxicity.
Inhibitors of LPXC are not yet marketed. Although research and application of LPXC inhibitors have advanced to some extent, there is still a great room for improvement in the treatment of people, and there is still a need to continue to research and develop new LPXC inhibitors.
Disclosure of Invention
Aiming at the technical problems, the invention provides an aromatic acetylene derivative shown in a general formula (I) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof:
wherein:
x and Y are each independently selected from C or N, and X, Y are not both N;
ring a is selected from 4-to 6-membered heteroaryl or 4-to 6-membered heterocyclyl, preferably 5-membered heteroaryl or 5-membered heterocyclyl;
L 1 selected from single bonds or-CH 2 -；
R 1 Identical or different, each independently selected from-G 1 -R 4 ；
G 1 Selected from single bond, -CH 2 -or-C (=o) -;
R 2 the same or different, each independently selected from hydroxy, cyano, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted with one or more substituents selected from halogen, hydroxy, cyano or alkoxy;
R 3 identical or different, each independently selected from hydroxy, cyano, halogen, alkyl, cycloalkyl, heterocyclyl, alkoxy or-C (O) R 5 Wherein said alkyl, cycloalkyl, heterocyclyl OR alkoxy is optionally further substituted with one OR more groups selected from halogen, hydroxy, cyano, alkoxy, -C (O) OR 5 or-C (O) NR 6 R 7 Is substituted by a substituent of (2);
R 4 selected from cyano, halogen, alkyl, hydroxy, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C (O) R 5 、-C(O)OR 5 、-OC(O)R 5 、-NR 6 R 7 、-C(O)NR 6 R 7 、-SO 2 NR 6 R 7 or-NR 6 C(O)R 7 Wherein said alkoxy, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted with one or more R A Substituted;
R A selected from halogen, hydroxy, amino, hydroxyalkyl, alkoxy, alkyl, cycloalkyl,Heterocyclyl, aryl, heteroaryl, -C (O) R 5 、-C(O)OR 5 、-OC(O)R 5 、-NR 6 R 7 、-C(O)NR 6 R 7 、-SO 2 NR 6 R 7 or-NR 6 C(O)R 7 Wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally further substituted with one or more moieties selected from the group consisting of halogen, hydroxy, amino, haloalkyl, hydroxyalkyl, alkoxy, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C (O) R 5 、-C(O)OR 5 、-OC(O)R 5 、-NR 6 R 7 、-C(O)NR 6 R 7 、-SO 2 NR 6 R 7 or-NR 6 C(O)R 7 Is substituted by a substituent of (a);
R 5 selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted with one or more groups selected from a hydroxyl group, a halogen group, a nitro group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, =o, -C (O) R 8 、-C(O)OR 8 、 -OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO 2 NR 9 R 10 or-NR 9 C(O)R 10 Is substituted by a substituent of (2);
R 6 and R is 7 Each independently selected from a hydrogen atom, hydroxy, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted with one or more groups selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =o, -C (O) R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO 2 NR 9 R 10 or-NR 9 C(O)R 10 Is substituted by a substituent of (2);
alternatively, R 6 And R is 7 Together with the atoms to which they are attached form a 4-8 membered heterocyclic group, wherein the 4-8 membered heterocyclic group contains one or more N, O, S or SO 2 And said 4-8 membered heterocyclyl is optionally further substituted with one or more substituents selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =o, -C (O) R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO 2 NR 9 R 10 or-NR 9 C(O)R 10 Is substituted by a substituent of (2);
R 8 、R 9 and R is 10 Each independently selected from the group consisting of hydrogen, alkyl, amino, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally further substituted with one or more substituents selected from the group consisting of hydroxy, halogen, nitro, amino, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxyl, or carboxylate;
m is 0, 1, 2 or 3;
n is 0, 1 or 2, n preferably being 0; and is also provided with
p is 0, 1 or 2.
According to a preferred embodiment of the present invention, there is provided a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which is a compound of formula (II):
wherein: ring A, R 1 ～R 3 、L 1 The definitions of m, n and p are as described in the general formula (I).
According to a preferred embodiment of the present invention, there is provided a compound of formula (II) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which is a compound of formula (III):
wherein:
R A selected from the group consisting of haloalkyl, hydroxyalkyl, alkoxy, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxyl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally further substituted with carboxyl;
q is 0, 1 or 2;
ring A, G 1 、R 2 、R 3 、L 1 The definition of n and p is as described in the general formula (I).
According to a preferred embodiment of the present invention there is provided a compound of formula (I), (II) or (III) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein ring a is selected from:
According to a preferred embodiment of the present invention, there is provided a compound of the general formula (I), (II) or (III) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein
Selected from:
according to a preferred embodiment of the present invention, there is provided a compound of the general formula (I) or (II) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein
Selected from:
according to a preferred embodiment of the present invention there is provided a compound of formula (I), (II) or (III) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein n is selected from 0.
According to a preferred embodiment of the present invention, there is provided a compound of formula (I), (II) or (III) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein L 1 Selected from-CH 2 -。
In a preferred embodiment of the invention, the compounds of formula (I) are selected from:
or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof.
Note that: if there is a difference between the drawn structure and the name given to the structure, the drawn structure will be given greater weight.
Still further, the present invention provides a pharmaceutical composition comprising an effective amount of a compound of formula (I), (II) or (III), or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
The invention provides an application of a compound shown in a general formula (I), (II) or (III) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof in preparing an LPXC inhibitor.
The invention also provides the use of a compound of formula (I), (II) or (III), or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, for the manufacture of a medicament for the treatment of a disease mediated by LPXC, wherein the disease mediated by LPXC is preferably a bacterial infection caused by gram-negative bacteria; wherein the LPXC-mediated disease is selected from bacterial infections caused by gram-negative bacteria such as Escherichia coli, pseudomonas aeruginosa, proteus, bacillus dysenteriae, bacillus pneumoniae, brucella, typhoid bacillus, acinetobacter, yersinia, legionella pneumophila, pertussis bacillus, shigella, pasteurella, vibrio cholerae, and Neisseria meningitidis.
The invention further provides application of the compound shown in the general formula (I), (II) or (III) or stereoisomer, tautomer or pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof in preparing medicines for treating bacterial infection caused by gram-negative bacteria.
The invention provides an application of a compound shown in a general formula (I), (II) or (III) or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof in preparing medicines for treating bacterial infections caused by gram-negative bacteria such as escherichia coli, pseudomonas aeruginosa, bacillus proteus, shigella dysenteriae, pneumobacillus, bacillus typhi, acinetobacter, yersinia, legionella pneumophila, pertussis bacillus, shigella, pasteurella, vibrio cholerae, meningococcus and the like.
The present invention also provides a method of treating a disease mediated by LPXC comprising administering to a subject in need thereof a compound of formula (I), (II) or (III), or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. Preferably, the disease mediated by LPXC is a bacterial infection caused by gram negative bacteria; more preferably, the gram-negative bacteria are selected from the group consisting of E.coli, pseudomonas aeruginosa, proteus, bacillus dysenteriae, bacillus pneumoniae, brucella, typhoid bacillus, acinetobacter, yersinia, legionella pneumophila, pertussis bacillus, shigella, pasteurella, vibrio cholerae, and Neisseria meningitidis.
Detailed description of the invention
Unless stated to the contrary, some of the terms used in the specification and claims of the present invention are defined as follows:
"alkyl" when taken as a group or part of a group is meant to include C 1 -C 20 Straight chain or branched aliphatic hydrocarbon groups. Preferably C 1 -C 10 An alkyl group, a hydroxyl group,more preferably C 1 -C 6 Alkyl or C 1 -C 4 An alkyl group. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-dimethylpropyl, 1, 2-dimethylpropyl, 2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1, 2-trimethylpropyl, 1-dimethylbutyl, 1, 2-dimethylbutyl, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2, 3-dimethylbutyl, and the like. Alkyl groups may be substituted or unsubstituted.
"cycloalkyl" refers to a non-aromatic cyclic alkyl group wherein one or more of the ring-forming atoms are carbon atoms, including monocyclic, polycyclic, fused, bridged and spiro rings, preferably having 3 to 7 membered monocyclic or 7 to 10 membered bicyclic or tricyclic rings. Examples of "cycloalkyl" include, but are not limited to, cyclopropyl, cyclopentyl, cyclobutyl. Cycloalkyl groups may be substituted or unsubstituted. Preferably C 3 -C 7 Cycloalkyl, C 3 -C 6 Cycloalkyl or C 5 -C 7 Cycloalkyl groups.
"spirocycloalkyl" refers to a 5 to 18 membered, two or more cyclic structure, and monocyclic polycyclic groups sharing one carbon atom (called spiro atom) with each other, containing 1 or more double bonds within the ring, but no ring has a completely conjugated pi-electron aromatic system. Preferably 6 to 14 membered, more preferably 7 to 10 membered. The spirocycloalkyl group is classified into a single spiro group, a double spiro group or a multiple spirocycloalkyl group according to the number of common spiro atoms between rings, preferably single spiro group and double spirocycloalkyl group, preferably 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered or 5-membered/6-membered. Non-limiting examples of "spirocycloalkyl" include, but are not limited to: spiro [4.5] decyl, spiro [4.4] nonyl, spiro [3.5] nonyl, spiro [2.4] heptyl.
"fused ring alkyl" refers to an all-carbon polycyclic group containing two or more cyclic structures sharing a pair of carbon atoms with each other, one or more of the rings may contain one or more double bonds, but none of the rings has a fully conjugated pi-electron aromatic system, preferably 6 to 12 members, more preferably 7 to 10 members. The number of constituent rings may be classified as a bicyclic, tricyclic, tetracyclic or polycyclic fused ring alkyl group, preferably a bicyclic or tricyclic, more preferably a 5-membered/5-membered or 5-membered/6-membered bicycloalkyl group. Non-limiting examples of "fused ring alkyl" include, but are not limited to: bicyclo [3.1.0] hexyl, bicyclo [3.2.0] hept-1-enyl, bicyclo [3.2.0] heptyl, decalinyl, or tetradecahydrophenanthryl.
"bridged cycloalkyl" means an aromatic system having 5 to 18 members, containing two or more cyclic structures, sharing two all-carbon polycyclic groups with one another that are not directly attached to a carbon atom, one or more of the rings may contain one or more double bonds, but none of the rings has a fully conjugated pi electron, preferably 6 to 12 members, more preferably 7 to 10 members. Preferably 6 to 14 membered, more preferably 7 to 10 membered. Cycloalkyl groups which may be classified as bicyclic, tricyclic, tetracyclic or polycyclic bridged according to the number of constituent rings are preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of "bridged cycloalkyl" include, but are not limited to: (1 s,4 s) -bicyclo [2.2.1] heptyl, bicyclo [3.2.1] octyl, (1 s,5 s) -bicyclo [3.3.1] nonyl, bicyclo [2.2.2] octyl, and (1 r,5 r) -bicyclo [3.3.2] decyl.
"heterocyclyl", "heterocycloalkyl", "heterocycle" or "heterocyclic" are used interchangeably herein to refer to a non-aromatic heterocyclic group in which one or more of the ring-forming atoms is a heteroatom such as oxygen, nitrogen or S (O) r (wherein r is selected from 0, 1 or 2), and the ring atoms optionally include-C (=o) -, including monocyclic, polycyclic, fused, bridged and spiro rings. Preferably having 5 to 7 membered mono-or 7 to 10 membered bi-or tricyclic ring, which may contain 1,2 or 3 groups selected from nitrogen, oxygen and/or S (O) r (wherein r is selected from an atom in 0, 1 or 2). Examples of "heterocyclyl" include, but are not limited to, morpholinyl, oxetanyl, thiomorpholinyl, tetrahydrofuranyl, tetrahydropyranyl, 1-dioxo-thiomorpholinyl, piperidinyl, 2-oxo-piperidinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperazin-2-one, 8-oxa-3-aza-bicyclo [3.2.1]Octyl, piperazinyl, hexahydropyrimidine,
The heterocyclic group may be substituted or unsubstituted.
"spiroheterocyclyl" refers to a 5 to 18 membered, two or more cyclic structure, polycyclic group having single rings sharing one atom with each other, containing 1 or more double bonds within the ring, but no ring having a fully conjugated pi-electron aromatic system wherein one or more ring atoms are selected from nitrogen, oxygen, C (=o) or S (O) r (wherein r is selected from 0, 1 or 2) and the remaining ring atoms are carbon. Preferably 6 to 14 membered, more preferably 7 to 10 membered. The spirocycloalkyl group is classified into a single spiro heterocyclic group, a double spiro heterocyclic group or a multiple spiro heterocyclic group according to the number of common spiro atoms between rings, and preferably a single spiro heterocyclic group and a double spiro heterocyclic group. More preferably a 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered or 5-membered/6-membered single spiro heterocyclic group. Non-limiting examples of "spiroheterocyclyl" include, but are not limited to: 1, 7-dioxaspiro [4.5 ] ]Decyl, 2-oxa-7-azaspiro [4.4 ]]Nonyl, 7-oxaspiro [3.5 ]]Nonyl, 5-oxaspiro [2.4 ]]A heptyl group.
"fused heterocyclyl" refers to a polycyclic group containing two or more cyclic structures sharing a pair of atoms with each other, one or more of the rings may contain one or more double bonds, but none of the rings has a fully conjugated pi-electron aromatic system in which one or more of the ring atoms is selected from nitrogen, oxygen, C (=o) or S (O) r (wherein r is selected from 0, 1 or 2) and the remaining ring atoms are carbon. Preferably 6 to 14 membered, more preferably 7 to 10 membered. The number of constituent rings may be classified as a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group, preferably a bicyclic or tricyclic, more preferably a 5-membered/5-membered or 5-membered/6-membered bicyclic fused heterocyclic group. Non-limiting "fused heterocyclyl" groupsIllustrative embodiments include, but are not limited to: octahydropyrrolo [3,4-c ]]Pyrrolyl, octahydro-1H-isoindolyl, 3-azabicyclo [3.1.0 ]]Hexyl, octahydrobenzo [ b ]][1,4]Dioxin (dioxin) is used,
"bridged heterocyclyl" means a 5 to 14 membered, 5 to 18 membered, polycyclic group containing two or more cyclic structures sharing two atoms not directly attached to each other, one or more of the rings may contain one or more double bonds, but none of the rings has a fully conjugated pi-electron aromatic system in which one or more of the ring atoms is selected from nitrogen, oxygen, C (=o) or S (O) r (wherein r is selected from 0, 1 or 2) and the remaining ring atoms are carbon. Preferably 6 to 14 membered, more preferably 7 to 10 membered. Heterocyclic groups which may be classified as bicyclic, tricyclic, tetracyclic or polycyclic bridged according to the number of constituent rings are preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of "bridged heterocyclyl" include, but are not limited to: 2-azabicyclo [2.2.1]Heptyl, 2-azabicyclo [2.2.2]Octyl, 2-azabicyclo [3.3.2]And (3) a decyl group.
"aryl" refers to a carbocyclic aromatic system containing one or two rings, wherein the rings may be linked together in a fused manner. The term "aryl" includes monocyclic or bicyclic aryl groups such as phenyl, naphthyl, tetrahydronaphthyl aromatic groups. Preferably aryl is C 6 -C 10 Aryl, more preferably aryl is phenyl and naphthyl, most preferably naphthyl. Aryl groups may be substituted or unsubstituted.
"heteroaryl" refers to an aromatic 5-to 6-membered monocyclic or 8-to 10-membered bicyclic ring, which may contain 1 to 4 atoms selected from nitrogen, oxygen and/or sulfur. Preferred heteroaryl groups are C 6 -C 10 Heteroaryl groups containing 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur. Examples of "heteroaryl" include, but are not limited to, furyl, pyridyl, 2-oxo-1, 2-dihydropyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, Oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2, 3-thiadiazolyl, benzodioxolyl, benzothienyl, benzimidazolyl, indolyl, isoindolyl, 1, 3-dioxo-isoindolyl, quinolinyl, indazolyl, benzisothiazolyl, benzoxazolyl, benzisoxazolyl, isothiazolyl, 1H-1,2, 4-triazolyl, 4H-1,2, 4-triazolyl, pyridinyl, pyrimidinyl, pyrazin-2 (1H) -one, pyrimidin-4 (3H) -one, pyridazin-3 (2H) -one, 1H-indolyl, 1H-benzo [ d ]]Imidazolyl, 1H-pyrrolo [2,3-c]Pyridyl, 3H-imidazo [4,5-c ]]Pyridinyl, isoquinolinyl, quinazolinyl, 2H-isoindolyl, and furan [3,2-b ]]Pyridyl and furan [2,3-c ]]Pyridinyl, thieno [2,3-c]Pyridyl, benzofuranyl and benzo [ b ]]Thienyl, 1H-pyrrolo [3,2-b]Pyridyl, 2H-pyrrolo [3,4-c]A pyridyl group. Heteroaryl groups may be substituted or unsubstituted.
"alkoxy" refers to a group of (alkyl-O-). Wherein alkyl is as defined herein. C (C) 1 -C 6 Or C 1 -C 4 Is preferably selected. Examples include, but are not limited to: methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy and the like.
"nitro" means-NO 2 A group.
"hydroxy" refers to an-OH group.
"halogen" refers to fluorine, chlorine, bromine and iodine.
"amino" means-NH 2 。
"cyano" refers to-CN.
"benzyl" means-CH 2 -phenyl.
"carboxy" means-C (O) OH.
"carboxylate" refers to-C (O) O-alkyl or-C (O) O-cycloalkyl, wherein alkyl, cycloalkyl are as defined above.
"hydroxyalkyl" refers to hydroxy-substituted alkyl groups, wherein alkyl is as defined above.
"aminoalkyl" refers to an amino-substituted alkyl group, wherein the alkyl group is as defined above.
"haloalkyl" refers to a halogen substituted alkyl group, wherein alkyl is as defined above.
"haloalkoxy" refers to a halogen substituted alkoxy group, wherein the definition of alkoxy is as described above.
"DMSO" refers to dimethyl sulfoxide.
"BOC" refers to t-butoxycarbonyl.
"Bn" refers to benzyl.
"THP" refers to 2-tetrahydropyranyl.
"TFA" refers to trifluoroacetic acid.
"Ts" refers to p-toluenesulfonyl.
The term "leaving group", or "leaving group", is used in the term nucleophilic substitution reaction and elimination reaction as an atom or functional group that is released from a larger molecule in a chemical reaction. In nucleophilic substitution reactions, the reactant that is attacked by a nucleophile is referred to as a substrate (substrate), and the atom or group of atoms that breaks away from a pair of electrons in the substrate molecule is referred to as a leaving group. Groups that accept electrons easily and bear a strong negative charge are good leaving groups. The smaller the pKa of the leaving group conjugate acid, the easier the leaving group will be to disengage from the other molecule. The reason is that when the pKa of its conjugate acid is smaller, the corresponding leaving group does not need to be bound to other atoms, and the tendency to exist in anionic (or charge neutral leaving group) form is enhanced. Common leaving groups include, but are not limited to, halogen, methanesulfonyl, -OTs, or-OH.
"substituted" means that one or more hydrogen atoms, preferably up to 5, more preferably 1 to 3 hydrogen atoms in the group are independently substituted with a corresponding number of substituents. It goes without saying that substituents are only in their possible chemical positions, and that the person skilled in the art is able to determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxyl groups having free hydrogen may be unstable when bound to carbon atoms having unsaturated (e.g., olefinic) bonds.
The specification of the present applicationThe terms "substituted" or "substituted", unless otherwise indicated, mean that a group may be substituted with one or more groups selected from the group consisting of: alkyl, alkoxy, alkylthio, alkylamino, halogen, nitro, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, amino, haloalkyl, hydroxyalkyl, carboxyl, carboxylate, =o, -C (O) R 5 、-C(O)OR 5 、-OC(O)R 5 、-NR 6 R 7 、-C(O)NR 6 R 7 、-SO 2 NR 6 R 7 or-NR 6 C(O)R 7 ；
R 5 Selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted with one or more groups selected from a hydroxyl group, a halogen group, a nitro group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, =o, -C (O) R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO 2 NR 9 R 10 or-NR 9 C(O)R 10 Is substituted by a substituent of (2);
R 6 and R is 7 Each independently selected from a hydrogen atom, hydroxy, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted with one or more groups selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =o, -C (O) R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO 2 NR 9 R 10 or-NR 9 C(O)R 10 Is substituted by a substituent of (2);
alternatively, R 6 And R is 7 Together with the atoms to which they are attached form a 4-8 membered heterocyclic group, wherein the 4-8 membered heterocyclic group contains one or more N, O, S or SO 2 And said 4-8 membered heterocyclyl is optionally further substituted with one or more substituents selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =o, -C (O) R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO 2 NR 9 R 10 or-NR 9 C(O)R 10 Is substituted by a substituent of (2);
R 8 、R 9 and R is 10 Each independently selected from the group consisting of hydrogen, alkyl, amino, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally further substituted with one or more substituents selected from the group consisting of hydroxy, halogen, nitro, amino, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxyl, and carboxylate.
"pharmaceutically acceptable salts" refers to certain salts of the above compounds which retain the original biological activity and are suitable for pharmaceutical use. The pharmaceutically acceptable salts of the compounds represented by the general formula (I) may be metal salts, amine salts with suitable acids.
"pharmaceutical composition" means a mixture comprising one or more of the compounds described herein or a physiologically acceptable salt or prodrug thereof, and other chemical components, as well as other components such as a physiologically acceptable carrier. The purpose of the pharmaceutical composition is to promote the administration to organisms, facilitate the absorption of active ingredients and thus exert biological activity.
Synthesis method of compound of the invention
In order to achieve the purpose of the invention, the invention adopts the following technical scheme:
the present invention provides a process for the preparation of a compound of formula (I) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, which process comprises:
coupling the compound of the general formula (I-a) with the compound of the general formula (I-b) under the action of a catalyst, and optionally removing the protecting group to obtain the compound of the general formula (I);
wherein:
X 1 selected from halogen;
ring A, X, Y, R 1 ～R 3 、L 1 The definitions of n, m and p are as described in the general formula (I).
Detailed Description
The invention will be further described with reference to the following examples, which are not intended to limit the scope of the invention.
Examples
The preparation of representative compounds represented by formula (I) and related structural identification data are presented in the examples. It must be noted that the following examples are given by way of illustration and not by way of limitation. 1 The H NMR spectrum was determined with a Bruker instrument (400 MHz) and the chemical shifts were expressed in ppm. Tetramethylsilane internal standard (0.00 ppm) was used. 1 H NMR representation method: s=singlet, d=doublet, t=triplet, m=multiplet, br=broadened, dd=doublet of doublet, dt=doublet of triplet. If coupling constants are provided, they are in Hz.
The mass spectrum is measured by an LC/MS instrument, and the ionization mode can be ESI or APCI.
The thin layer chromatography silica gel plate uses a smoke table yellow sea HSGF254 or Qingdao GF254 silica gel plate, the specification of the silica gel plate used by the Thin Layer Chromatography (TLC) is 0.15 mm-0.2 mm, and the specification of the thin layer chromatography separation and purification product is 0.4 mm-0.5 mm.
Column chromatography generally uses tobacco stand yellow sea silica gel 200-300 mesh silica gel as a carrier.
In the following examples, unless otherwise indicated, all temperatures are in degrees celsius and, unless otherwise indicated, various starting materials and reagents are either commercially available or synthesized according to known methods, all of which are used without further purification and, unless otherwise indicated, commercially available manufacturers include, but are not limited to, aldrich Chemical Company, ABCR GmbH & co.kg, acros Organics, praise chemical technology limited, and vision chemical technology limited, etc.
CD 3 OD: deuterated methanol.
CDCl 3 : deuterated chloroform.
DMSO-d 6 : deuterated dimethyl sulfoxide.
The argon atmosphere means that the reaction flask is connected to an argon balloon of about 1L volume.
The examples are not particularly described, and the solution in the reaction is an aqueous solution.
Purifying the compound by using a silica gel column chromatography eluent system and thin layer chromatography, wherein the eluent system is selected from the group consisting of: a: petroleum ether and ethyl acetate systems; b: methylene chloride and methanol systems; c: dichloromethane and ethyl acetate systems; the volume ratio of the solvent is different according to the polarity of the compound, and can be adjusted by adding a small amount of acidic or alkaline reagent, such as acetic acid or triethylamine.
Example 1
5-hydroxy-6- (3- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -4, 5-dihydro-isoxazol-5-yl) pyrimidin-4 (3H) -one
First step
(E) -4-iodobenzaldehyde oxime
Hydroxylamine hydrochloride (5.99 g,86.20 mmol), potassium carbonate (11.9 g,86.20 mmol), 4-iodobenzaldehyde 1a (10 g,43.10 mmol) and water (80 mL) were added sequentially to ethanol (80 mL) and reacted overnight at room temperature. After the completion of the reaction, the organic phases were combined by extraction with ethyl acetate (100 mL. Times.3), and the obtained residue was purified by silica gel column chromatography (eluent: A system) to give (E) -4-iodobenzaldehyde oxime 1b (8 g), yield: 75.14%.
MS m/z(ESI):247.8[M+1] +
Second step
(Z) -N-hydroxy-4-iodobenzilimide chloride
(E) -4-iodobenzaldehyde oxime 1b (1 g,4.05 mmol) was dissolved in N, N-dimethylformamide (10 mL), chlorosuccinimide (594.59 mg,4.45 mmol) was slowly added thereto, and the reaction was stirred at room temperature overnight. After the reaction was completed, the (Z) -N-hydroxy-4-iodobenzil chloride 1c was obtained, and the reaction solution was directly used for the next reaction without purification.
Third step
5- (5, 6-bis (benzyloxy) pyrimidin-4-yl) -3- (4-iodophenyl) -4, 5-dihydroisoxazole
4, 5-bis (benzyloxy) -6-vinyl pyrimidine 1d (1.1 g,3.46mmol, prepared according to patent WO 2020061375) and triethylamine (699.25 mg,6.91mmol, 957.87. Mu.L) were dissolved in N, N-dimethylformamide (14.04 mL), and a solution of (Z) -N-hydroxy-4-iodobenzil chloride 1c (972.54 mg,3.46 mmol) in N, N-dimethylformamide (10 mL) was slowly added dropwise and reacted at room temperature for 6 hours. After completion of the reaction, the reaction was quenched with water, extracted with ethyl acetate (50 mL. Times.3), the organic phases were combined, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: A system) to give 5- (5, 6-bis (benzyloxy) pyrimidin-4-yl) -3- (4-iodophenyl) -4, 5-dihydroisoxazole 1e (1.4 g), yield: 71.92%.
MS m/z(ESI):563.8[M+1] +
Fourth step
4- (4- ((4- (5, 6-bis (benzyloxy)) pyrimidin-4-yl) -4, 5-dihydroisoxazol-3-yl) phenyl) ethynyl) benzyl) morpholine
5- (5, 6-bis (benzyloxy) pyrimidin-4-yl) -3- (4-iodophenyl) -4, 5-dihydroisoxazole 1e (0.8 g,1.42 mmol), 4- (4-ethynylbenzyl) morpholine 1f (285.79 mg,1.42 mmol), bis (triphenylphosphine) palladium dichloride (199.34 mg, 284.00. Mu. Mol), cuprous iodide (54.09 mg, 284.00. Mu. Mol) and triethylamine (431.07 mg,4.26 mmol) were dissolved in N, N-dimethylformamide (6 mL), replaced with argon three times and stirred at room temperature overnight. After completion of the reaction, the reaction was quenched with water, extracted with ethyl acetate (20 ml×3), the organic phases were combined, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: B system) to give 1g (0.85 g) of 4- (4- ((4- (5, 6-bis (benzyloxy)) pyrimidin-4-yl) -4, 5-dihydroisoxazol-3-yl) phenyl) ethynyl) benzyl) morpholine, yield: 94.01%.
MS m/z(ESI):637.0[M+1] +
Fifth step
5-hydroxy-6- (3- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -4, 5-dihydro-isoxazol-5-yl) pyrimidin-4 (3H) -one
1g (0.2 g, 314.10. Mu. Mol) of 4- (4- ((4- (5, 6-bis (benzyloxy)) pyrimidin-4-yl) -4, 5-dihydroisoxazol-3-yl) phenyl) ethynyl) benzyl) morpholine was dissolved in dichloromethane (2 mL) and boron trichloride (1.84 g,15.71mmol,5 mL) was slowly added dropwise and heated to 30℃for 6 hours. After the reaction is finished, adding a proper amount of methanol in an ice bath for quenching. Filtration under reduced pressure, followed by preparative liquid chromatography (separation column AKZONOBEL Kromasil; 250X 21.2mm I.D.;5 μm,20mL/min; mobile phase A:0.05% TFA+H) 2 O, mobile phase B: CH (CH) 3 CN) to give 5-hydroxy-6- (3- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -4, 5-dihydro-isoxazol-5-yl) pyrimidin-4 (3H) -one 1 (25 mg), yield: 13.67%.
MS m/z(ESI):457.2[M+1] +
Example 2
3- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) oxazolidin-2-one 2
First step
2-amino-1- (4-bromophenyl) ethan-1-ol
To a solution of 2-amino-1- (4-bromophenyl) ethan-1-one hydrochloride 2a (5 g,17.42 mmol) in tetrahydrofuran (100 mL) was added sodium borohydride (1.98 g,52.27 mmol), then ethanol (50 mL) was added, the reaction was carried out at room temperature for 2 hours, after the completion of the reaction, 30mL of water was added, ethyl acetate (40 mL. Times.3) was extracted, a saturated sodium chloride solution (20 mL) was washed, and the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure to give 2-amino-1- (4-bromophenyl) ethan-1-ol 2b (3.76 g), yield: 100% of the reaction mixture was directly subjected to the next reaction without purification.
MS m/z(ESI):216.0[M+1] +
Second step
5- (4-bromophenyl) oxazolidin-2-one
To a solution of 2-amino-1- (4-bromophenyl) ethan-1-ol 2b (3.76 g,17.40 mmol) and triethylamine (3.52 g,34.80mmol,4.84 mL) in methylene chloride (80 mL) at-78deg.C was added bis (trichloromethyl) carbonate (2.58 g,8.70 mmol), and the mixture was allowed to react at low temperature for 20 minutes and then allowed to react overnight at room temperature. To the reaction solution was added 20mL of water, extracted with dichloromethane (60 mL. Times.3), washed with saturated sodium chloride solution (30 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: B system) to give 5- (4-bromophenyl) oxazolidin-2-one 2c (2.62 g), yield: 62.2%.
MS m/z(ESI):242.0[M+1] +
Third step
3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4-bromophenyl) oxazolidin-2-one
Potassium carbonate (856.43 mg,6.20 mmol) was added to 5- (4-bromophenyl) oxazolidin-2-one 2c (500 mg,2.07 mmol) and 4, 5-bis (benzyloxy) -6- (iodomethyl) pyrimidine 2d (892.83 mg,2.07mmol, prepared according to patent WO 2020061375) in acetonitrile (40 mL), heated to reflux, reacted for 6 hours, after the reaction was completed, 20mL of water was added, ethyl acetate (20 mL. Times.3) was extracted, saturated sodium chloride solution (20 mL) was washed, the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: A system) to give 3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4-bromophenyl) oxazolidin-2-one 2e (0.94 g), yield: 83.29%.
MS m/z(ESI):546.1[M+1] +
Fourth step
3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) oxazolidin-2-one
3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4-bromophenyl) oxazolidin-2-one 2e (910 mg,1.67 mmol), 4- (4-ethynylbenzyl) morpholine 1f (435.74 mg,2.17 mmol), bis (triphenylphosphine) palladium dichloride (58.45 mg, 83.27. Mu. Mol), tetrabutylammonium bromide (536.88 mg,1.67 mmol) and piperidine (425.43 mg,5.00 mmol) were added to water (20 mL), argon was displaced three times and heated to 85℃for 4 hours. After the completion of the reaction, ethyl acetate (30 ml×3) was added to the reaction mixture to extract, a saturated sodium chloride solution (20 mL) was washed, the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: a system) to give 3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) oxazolidin-2-one 2f (0.835 g), yield: 75.2%.
MS m/z(ESI):667.3[M+1] +
Fifth step
3- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) oxazolidin-2-one
Boron trichloride (8 mL) was added to 3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) oxazolidin-2-one 2f (860 mg,1.29 mmol) in dichloromethane (3 mL) under ice-water bath conditions, the temperature was slowly raised to 35℃and after the reaction was completed, the reaction was quenched with methanol and concentrated under reduced pressure to give a liquid phase separation (separation column AKZONOBEL Kromasil; 250X 21.2mm I.D.;5 μm,20mL/min; mobile phase A:0.05% TFA+H) 2 O, mobile phase B: CH (CH) 3 CN) to give 3- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) oxazolidin-2-one 2 (100 mg), yield: 12.34％。
MS m/z(ESI):487.2[M+1] +
1 H NMR(400MHz,DMSO-d 6 )δ10.17(s,1H),9.66(s,1H),7.80(s,1H),7.68(d,J＝7.9Hz,2H),7.63(d,J＝8.2Hz,2H),7.57(d,J＝7.9Hz,2H),7.52(d,J＝8.1Hz,2H),5.62(dd,J＝8.8, 7.0Hz,1H),4.38(s,2H),4.32(s,2H),3.99(t,J＝8.9Hz,3H),3.65(s,2H),3.43(dd,J＝8.8,7.0Hz,1H),3.26(s,2H),3.13(s,2H).
example 3
3- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -5- (4- ((4- (morpholin-4-carbonyl) phenyl) ethynyl) phenyl) oxazolin-2-one
First step
3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- (((4- (morpholine-4-carbonyl) phenyl) ethynyl) phenyl) oxazolidin-2-one
3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4-bromophenyl) oxazolidin-2-one 2e (130 mg, 237.92. Mu. Mol), (4-ethynylphenyl) (morpholino) methanone 3a (51.21 mg, 237.92. Mu. Mol), bis (triphenylphosphine) palladium dichloride (8.35 mg, 11.90. Mu. Mol), tetrabutylammonium bromide (76.70 mg, 237.92. Mu. Mol) and piperidine (60.78 mg, 713.75. Mu. Mol) were added to water (3 mL), argon was displaced three times and heated to 85℃for 4 hours. After the completion of the reaction, ethyl acetate (20 mL. Times.3) was added to the reaction mixture to extract, a saturated sodium chloride solution (20 mL) was washed, the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: A system) to give 3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- (((4- (morpholin-4-carbonyl) phenyl) ethynyl) phenyl) oxazolidin-2-one 3b (130 mg), yield: 80.27%.
MS m/z(ESI):681.3[M+1] +
Second step
3- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -5- (4- ((4- (morpholin-4-carbonyl) phenyl) ethynyl) phenyl) oxazolin-2-one
Boron trichloride (1.5 mL) was added dropwise to 3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- (((4- (morpholin-4-carbonyl) phenyl) ethynyl) phenyl) oxazolidin-2-one 3b (130 mg, 190.97. Mu. Mol) dichloromethane (2 mL) under ice-water bath conditions, heated to 35℃and reacted for 5 hours, after the reaction was completed, the methanol quenched reaction was concentrated under reduced pressure to prepare a liquid phase separation (separation column AKZONOBEL Kromasil; 250X 21.2mm I.D.;5 μm,20mL/min; mobile phase A:0.05% TFA+H) 2 O, mobile phase B: CH (CH) 3 CN) to give 3- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -5- (4- ((4- (morpholine-4-carbonyl) phenyl) ethynyl) phenyl) oxazolin-2-one 3 (11.97 mg), yield: 9.96%.
MS m/z(ESI):501.2[M+1] +
1 H NMR(400MHz,DMSO-d 6 )δ9.14-9.51(m,4H),8.44(dd,J＝5.2,1.7Hz,1H),8.14(s,4H),7.20(dd,J＝16.8,11.0Hz,1H),6.62(dd,J＝16.9,1.7Hz,1H),5.92(dd,J＝10.8,1.8Hz,1H),5.09(d,J＝7.5Hz,2H),4.95(t,J＝7.5Hz,2H),4.88(t,J＝7.6Hz,1H),3.91(t,J＝6.7Hz,1H),3.64(s,1H),3.52(d,J＝6.1Hz,1H),3.45(s,1H),3.32(s,1H),3.29(d,J＝7.3Hz,2H).
Example 4
5-hydroxy-6- ((4- (4- ((4- (morpholin-4-carbonyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
(E) -3- (4-iodophenyl) acrylic acid
4-iodobenzaldehyde 1a (10 g,43.10 mmol), malonic acid (5.38 g,51.72 mmol) and ammonium acetate (6.64 g,86.20 mmol) were added to ethanol (10 mL), the mixture was refluxed for 6 hours, cooled to room temperature, after the reaction was completed, filtered, and the filter cake was washed once with ethanol and n-hexane 40mL each, and dried to give (E) -3- (4-iodophenyl) acrylic acid 4a (9.8 g), yield: 82.97%.
MS m/z(ESI):275.0[M+1] +
Second step
3-amino-3- (4-iodophenyl) propionic acid
(E) -3- (4-iodophenyl) acrylic acid 4a (6 g,21.89 mmol), ammonium acetate (5.06 g,65.68 mmol) and ethanol (50 mL) were added to the pressure tube, heated to reflux, reacted for 6 hours, cooled to room temperature after the reaction was completed, filtered, the filter cake was washed once with ethanol and n-hexane 40mL each, and the filter cake was dried to give 3-amino-3- (4-iodophenyl) propionic acid 4b (5 g), yield: 78.16%. MS m/z (ESI): 292.0[ M+1 ]] +
Third step
3- ((tert-Butoxycarbonyl) amino) -3- (4-iodophenyl) propanoic acid
Di-tert-butyl dicarbonate (5.51 g,25.25 mmol) was added to 4b 3-amino-3- (4-iodophenyl) propionic acid (4.9 g,16.83 mmol) in 50mL dioxane, followed by 50mL saturated sodium bicarbonate solution and stirred overnight at room temperature. After the reaction was completed, filtration, washing the cake with 50mL of n-hexane twice, acidifying the filtrate with citric acid solution, extracting with ethyl acetate (40 ml×3), washing with saturated sodium chloride solution (20 mL), drying the organic phase over anhydrous sodium sulfate, filtration, concentrating under reduced pressure, to give 3- ((t-butoxycarbonyl) amino) -3- (4-iodophenyl) propionic acid 4c (4.85 g), yield: 73.65%, and the next reaction was directly carried out without purification.
MS m/z(ESI):414.0[M+23] +
Fourth step
5- (4-iodophenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester
3- ((Boc) amino) -3- (4-iodophenyl) propanoic acid 4c (1 g,2.56 mmol), diphenyl azide phosphate (844.17 mg,3.07 mmol) and triethylamine (646.66 mg,6.39 mmol) were added to toluene (25 mL) and stirred at room temperature for 30 min. After the reaction was completed, 20mL of water was added to the reaction mixture, which was then extracted with ethyl acetate (20 mL. Times.3), and the saturated sodium chloride solution (20 mL) was washed, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give tert-butyl 5- (4-iodophenyl) -2-oxoimidazoline-1-carboxylate 4d (992 mg), yield: 99.97%, and the next reaction was directly carried out without purification.
MS m/z(ESI):333.0[M-55] +
Fifth step
3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4-iodophenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester
5- (4-iodophenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester 4d (800 mg,2.06 mmol), 4, 5-bis (benzyloxy) -6- (iodomethyl) pyrimidine 2d (890.79 mg,2.06 mmol), potassium carbonate (854.47 mg,6.18 mmol) were added to acetonitrile (5 mL), heated to 90 ℃ and reacted for 10 hours, after the reaction was completed, 20mL of water was added to the reaction solution, ethyl acetate (20 mL. Times.3) was extracted, saturated sodium chloride solution (20 mL) was washed, the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: A system) to give 3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4-iodophenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester 4e (510 mg), yield: 35.73%.
MS m/z(ESI):637.1[M-55] +
Sixth step
3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- ((4- (morpholine-4-carbonyl) phenyl) ethynyl) phenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester
3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4-iodophenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester 4e (100 mg, 154.91. Mu. Mol), (4-ethynylphenyl) (morpholino) methanone 3a (33.34 mg, 154.91. Mu. Mol), bis (triphenylphosphine) palladium dichloride (5.44 mg, 7.75. Mu. Mol), tetrabutylammonium bromide (49.94 mg, 154.91. Mu. Mol) and piperidine (39.57 mg, 464.73. Mu. Mol) were added to water (2 mL), argon was displaced three times, heated to 85℃and after the reaction was completed, 20mL of water was added to the reaction solution, ethyl acetate (20 mL. Times.3) was extracted, saturated sodium chloride solution (20 mL) was washed, the organic phase was dried over anhydrous sodium sulfate, filtered, and the resulting residue was purified by silica gel column chromatography (eluent: A system) to give 3- ((5, 6-bis (benzyloxy) pyrimidine-4-methyl) -4- (4-ethynylphenyl) -4-carboxylic acid tert-butyl ester (4-ethynylphenyl) -1-carboxylic acid) yield, 60mg, after the reaction was completed, the reaction was extracted, saturated sodium chloride solution was saturated sodium chloride solution (20 mL). 49.66%.
MS m/z(ESI):780.5[M+1] +
Seventh step
5-hydroxy-6- ((4- (4- ((4- (morpholin-4-carbonyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
Boron trichloride (1 mL) was added to 3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- ((4- (morpholin-4-carbonyl) phenyl) ethynyl) phenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester 4f (60 mg, 76.94. Mu. Mol) in methylene chloride (1 mL), heated to 35℃and reacted for 6 hours, after the reaction was completed, quenched with methanol, concentrated under reduced pressure to give a liquid phase separation (separation column AKZONOBEL Kromasil; 250X 21.2mm I.D.;5 μm,20mL/min; mobile phase A:0.05% TFA+H) 2 O, mobile phase B: CH (CH) 3 CN) to give 5-hydroxy-6- ((4- (4- ((4- (morpholine-4-carbonyl) phenyl) ethynyl) phenyl) -2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one 4 (8.58 mg), yield: 17.78%.
MS m/z(ESI):500.2[M+1] +
1 H NMR(400MHz,DMSO-d 6 )δ12.65(s,1H),9.31-9.76(m,1H),7.78(s,1H),7.59(dd,J＝18.8,8.0Hz,4H),7.45(dd,J＝12.0,8.0Hz,4H),7.10(d,J＝14.3Hz,1H),4.72(t,J＝8.1Hz,1H),4.19(d,J＝6.7Hz,2H),3.80(s,1H),3.63(s,8H),3.09(s,1H).
Example 5
5-hydroxy-6- ((3- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -4, 5-dihydroisoxazol-5-yl) methyl) pyrimidin-4 (3H) -one
Example 6
5-hydroxy-6- ((3- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -4, 5-dihydroisoxazol-4-yl) methyl) pyrimidin-4 (3H) -one
First step
4-allyl-5, 6-bis (benzyloxy) pyrimidine
Potassium phosphate (6.50 g,30.60 mmol), bis (triphenylphosphine) palladium dichloride (859.18 mg,1.22 mmol), 4, 5-dibenzyloxy-6-chloropyrimidine 5a (2.0 g,6.12mmol, prepared according to patent WO 2020102572) and 2-allyl-4, 5-tetramethyl-1, 3, 2-dioxaborane (4.11 g,24.48 mmol) were added sequentially to a mixed solution of tetrahydrofuran (20 mL) and water (4 mL), argon was replaced three times, and heated to 90℃for 20 hours. After completion of the reaction, water (10 mL) was added, extracted with ethyl acetate (10 mL. Times.3), and the combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: A system) to give 4-allyl-5, 6-bis (benzyloxy) pyrimidine 5b (250 mg), yield: 21.6%.
MS m/z(ESI):333.1[M+1] +
Second step
5- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3- (4-iodophenyl) -4, 5-dihydroisoxazole 5c
4- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3- (4-iodophenyl) -4, 5-dihydroisoxazole 5d
Pyridine (24.02 mg, 303.60. Mu. Mol), (E) -4-iodobenzaldehyde oxime 1b (250 mg,1.01 mmol) and 4-allyl-5, 6-bis (benzyloxy) pyrimidine 5b (504.58 mg,1.52 mmol) were successively added to a chloroform (5 mL) solution, and sodium hypochlorite solution (1.61 g,3.04 mmol) was slowly added dropwise under ice water bath cooling, and then warmed to room temperature and stirred for 3 hours. After completion of the reaction, water (10 mL) was added, extracted with ethyl acetate (10 mL. Times.3), the combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: A system) to give a mixture (470 mg) of 5- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3- (4-iodophenyl) -4, 5-dihydroisoxazole 5c and 4- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3- (4-iodophenyl) -4, 5-dihydroisoxazole 5d, yield: 80.4%.
MS m/z(ESI):578.1[M+1] +
Third step
4- (4- ((4- (5- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4, 5-dihydro-isoxazol-3-yl) phenyl) ethynyl) benzyl) morpholine 5e
4- (4- ((4- (4- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4, 5-dihydro-isoxazol-3-yl) phenyl) ethynyl) benzyl) morpholine 5f
A mixture (470 mg, 813.98. Mu. Mol) of the above 5- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3- (4-iodophenyl) -4, 5-dihydroisoxazole 5c and 4- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3- (4-iodophenyl) -4, 5-dihydroisoxazole 5d, 4- (4-ethynylbenzyl) morpholine 1f (163.82 mg, 813.98. Mu. Mol), allylpalladium chloride dimer (29.78 mg, 81.40. Mu. Mol), 1, 4-diazabicyclooctane (182.61 mg,1.63 mmol) and tri-tert-butylphosphine (16.47 mg, 81.40. Mu. Mol) was added to a solution of acetonitrile (10 mL), argon was replaced three times, and reacted at room temperature for 20 hours. After completion of the reaction, water (10 mL) was added. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure, and the resulting residue was purified by column chromatography on silica gel (eluent: A system) to give 4- (4- ((4- (5- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4, 5-dihydroisoxazol-3-yl) phenyl) ethynyl) benzyl) morpholine 5e (210 mg) and 4- (4- ((4- (4- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4, 5-dihydroisoxazol-3-yl) phenyl) ethynyl) benzyl) morpholine 5f (110 mg) in 39.6% and 20.8% yields, respectively.
MS m/z(ESI):651.2[M+1] +
MS m/z(ESI):651.0[M+1] +
Fourth step
5-hydroxy-6- ((3- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -4, 5-dihydroisoxazol-5-yl) methyl) pyrimidin-4 (3H) -one
4- (4- ((4- (5- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4, 5-dihydroisoxazol-3-yl) phenyl) ethynyl) benzyl) morpholine 5e (100 mg, 153.67. Mu. Mol) was dissolved in dichloromethane (2 mL) and 1M solution of boron trichloride in dichloromethane (2 mL) was slowly added dropwise with ice water bath cooling, then warmed to room temperature and stirred for 20 hours. After completion of the reaction, quenched with methanol (2 mL), concentrated under reduced pressure to give a liquid phase separation (separation column AKZONOBEL Kromasil; 250X 21.2mm I.D.;5 μm,20mL/min; mobile phase A:0.05% TFA+H) 2 O, mobile phase B: CH (CH) 3 CN) to give 5-hydroxy-6- ((3- (4- ((4- (morpholinomethyl) phenyl) ethynyl)) Phenyl) -4, 5-dihydro-isoxazol-5-yl-methyl) pyrimidin-4 (3H) -one 5 (6.7 mg), yield: 18.5%.
MS m/z(ESI):470.8[M+1] +
Fifth step
5-hydroxy-6- ((3- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -4, 5-dihydroisoxazol-4-yl) methyl) pyrimidin-4 (3H) -one
4- (4- ((4- (4- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4, 5-dihydroisoxazol-3-yl) phenyl) ethynyl) benzyl) morpholine 5f (110 mg, 169. Mu. Mol) was added to a solution of dichloromethane (2 mL), 1M solution of boron trichloride in dichloromethane (2 mL) was slowly added dropwise with ice water bath cooling, then warmed to room temperature and stirred for 20 hours. After completion of the reaction, quenched with methanol (2 mL), concentrated under reduced pressure to give a liquid phase separation (separation column AKZONOBEL Kromasil; 250X 21.2mm I.D.;5 μm,20mL/min; mobile phase A:0.05% TFA+H) 2 O, mobile phase B: CH (CH) 3 CN) to give 5-hydroxy-6- ((3- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -4, 5-dihydro-isoxazol-4-yl) methyl) pyrimidin-4 (3H) -one 6 (27 mg), yield: 27.2%.
MS m/z(ESI):471.1[M+1] +
Example 7
5-hydroxy-6- ((4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxopyrrolidin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
(E) -3- (4-iodophenyl) acrylic acid methyl ester
To a solution of potassium t-butoxide (2.90 g,25.86 mmol) in tetrahydrofuran (50 mL) was slowly added dropwise methyl 2- (ethoxy (propyl) phosphoryl) acetate 7a (5.43 g,25.86 mmol) under an argon atmosphere at zero degrees Celsius for 30 minutes, and a solution of 4-iodobenzaldehyde 1a (5 g,21.55 mmol) in tetrahydrofuran (10 mL) was added. The mixture was warmed to room temperature and stirred for 3 hours. After the completion of the reaction, the reaction was quenched with water (30 mL), extracted with ethyl acetate (30 mL. Times.3), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give methyl (E) -3- (4-iodophenyl) acrylate 7b (6 g), yield: 96.65%, and the next reaction was directly carried out without purification.
MS m/z(ESI):288.6[M+1] +
Second step
3- (4-iodophenyl) -4-nitrobutanoic acid methyl ester
To nitromethane (15 mL) was added 1, 8-diazabicyclo [5.4.0] undec-7-ene (1.59 g,10.41 mmol) and methyl (E) -3- (4-iodophenyl) acrylate 7b (3 g,10.41 mmol) at-10deg.C, stirred for 1 hour, slowly warmed to room temperature and stirred for 5 hours. After the completion of the reaction, the reaction was quenched with water (10 mL), the system was acidified with a dilute hydrochloric acid solution, extracted with ethyl acetate (30 mL. Times.3), the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: A system) to give methyl 3- (4-iodophenyl) -4-nitrobutyrate 7c (3.1 g), yield: 85.27%.
1 H NMR(400MHz,DMSO-d 6 )δ7.62-7.72(m,2H),7.12-7.19(m,2H),4.96(dd,J＝13.3,5.9Hz,1H),4.85(dd,J＝13.3,9.5Hz,1H),3.77(ddd,J＝9.1,6.0,3.0Hz,1H),3.52(s,3H),2.82(dd,J＝16.3,6.3Hz,1H),2.71(dd,J＝16.3,8.6Hz,1H).
Third step
4- (4-iodophenyl) pyrrolidin-2-one
Methyl 3- (4-iodophenyl) -4-nitrobutanoate 7c (500 mg,1.43 mmol) was added to methanol (10 mL), nickel chloride (92.80 mg, 716.08. Mu. Mol) was added, and after 5 minutes of reaction, sodium borohydride (108.36 mg,2.86 mmol) was added and the reaction was carried out at room temperature overnight. Saturated aqueous ammonium chloride solution was added at zero degrees celsius, followed by extraction with ethyl acetate (30 ml×2), the aqueous layer was separated, the combined organic phases were washed sequentially with saturated aqueous sodium chloride solution (30 ml×2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: a system) to give 4- (4-iodophenyl) pyrrolidin-2-one 7d (200 mg), yield: 48.64%.
MS m/z(ESI):287.9[M+1] +
Fourth step
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) pyrrolidin-2-one
4- (4-iodophenyl) pyrrolidin-2-one 7d (184 mg, 640.90. Mu. Mol) and 4, 5-bis (benzyloxy) -6- (iodomethyl) pyrimidine 2d (277.03 mg, 640.90. Mu. Mol) were added to acetonitrile (5 mL), cesium carbonate (835.27 mg,2.56 mmol) was added, and the mixture was heated to 100℃and reacted for 4 hours. The reaction solution was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was removed, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: B system) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) pyrrolidin-2-one 7e (110 mg), yield: 29.02%.
MS m/z(ESI):591.8[M+1] +
Fifth step
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) pyrrolidin-2-one
To an aqueous solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) pyrrolidin-2-one 7e (100 mg, 169.08. Mu. Mol) was added bis (triphenylphosphine) palladium dichloride (4.75 mg, 6.76. Mu. Mol), tetrabutylammonium bromide (54.51 mg, 169.08. Mu. Mol) and piperidine (43.19 mg, 507.24. Mu. Mol) at room temperature. The reaction was warmed to 70℃and stirred for 5 hours. The reaction solution was extracted with ethyl acetate (30 ml×2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 ml×2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: B system) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) pyrrolidin-2-one 7f (60 mg), yield: 53.38%.
MS m/z(ESI):665.0[M+1] +
Sixth step
5-hydroxy-6- ((4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxopyrrolidin-1-yl) methyl) pyrimidin-4 (3H) -one
Boron trichloride (1 mL) was added dropwise to 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) pyrrolidin-2-one 7f (60 mg, 90.25. Mu. Mol) in dichloromethane (2 mL) under ice-water bath conditions, reacted at room temperature for 2 hours, after completion of the reaction, quenched with methanol (2 mL), concentrated under reduced pressure to give a liquid phase separation (separation column AKZONOBEL Kromasil; 250X 21.2mm I.D.;5 μm,20mL/min; mobile phase A:0.05% TFA+H) 2 O, mobile phase B: CH (CH) 3 CN) to give 5-hydroxy-6- ((4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxopyrrolidin-1-yl) methyl) pyrimidin-4 (3H) -one 7 (13 mg), yield: 22.47%.
MS m/z(ESI):485.2[M+1] +
1 H NMR(400MHz,DMSO-d 6 )δ10.22(s,1H),9.57(s,1H),7.77(s,1H),7.66(d,J＝7.9Hz,2H),7.54(dd,J＝14.6,8.0Hz,4H),7.39(d,J＝8.0Hz,2H),4.37(q,J＝9.0,8.6Hz,4H),3.96(s,2H),3.74(t,J＝8.8Hz,2H),3.60-3.65(m,2H),3.29-3.33(m,1H),3.06-3.26(m,4H),2.75(dd,J＝16.5,9.0Hz,1H),2.38(dd,J＝16.5,8.1Hz,1H).
Example 8
5-hydroxy-6- ((4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester
3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4-iodophenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester 4e (1 g,1.44 mmol), 4- (4-ethynylbenzyl) morpholine 1f (311.77 mg,1.55 mmol), bis (triphenylphosphine) palladium dichloride (54.37 mg, 77.45. Mu. Mol), tetrabutylammonium bromide (499.38 mg,1.55 mmol) and piperidine (395.71 mg,4.65 mmol) were added to water (2 mL), replaced three times with argon, heated to 85 ℃ C., reacted for 4 hours, 20mL of water was added to the reaction solution, extracted with ethyl acetate (20 mL. Times.3), the saturated sodium chloride solution (20 mL) was washed, the organic phase was dried over anhydrous sodium sulfate, filtered and the resulting residue was purified by silica gel column chromatography (eluent: A system) to give 3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4-methylphenyl) -morpholine tert-8- ((8-ethynylmorpholine) yield (660 mg): 55.63%.
MS m/z(ESI):766.4[M+1] +
Second step
5-hydroxy-6- ((4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
Boron trichloride (0.5 mL) and 3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester 8a (60 mg, 78.34. Mu. Mol) in dichloromethane (1 mL) were slowly warmed to room temperature under ice-water bath conditions and reacted overnight. After completion of the reaction, quenched with methanol (2 mL), concentrated under reduced pressure to give a liquid phase separation (separation column AKZONOBEL Kromasil; 250X 21.2mm I.D.;5 μm,20mL/min; mobile phase A:0.05% TFA+H) 2 O, mobile phase B: CH (CH) 3 CN) to give 5-hydroxy-6- ((4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one 8 (11.54 mg), yield: 23.78%.
MS m/z(ESI):486.2[M+1] +
1 H NMR(400MHz,DMSO-d 6 )δ10.64(s,1H),9.57(s,1H),7.83(s,1H),7.71(d,J＝8.0Hz,2H),7.57-7.69(m,4H),7.49(d,J＝8.1Hz,2H),7.14(s,1H),4.79(t,J＝8.1Hz,1H),4.44(s,2H),4.25(d,J＝9.6Hz,2H),3.86(s,2H),3.77(s,2H),3.23-3.44(m,3H),3.04-3.24(m,3H).
Example 9
5-hydroxy-6- ((3- (2-fluoroethyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one
Hydrochloric acid (457.00 mg,12.53 mmol) was added to a solution of 3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester 8a (480 mg, 626.72. Mu. Mol) in ethyl acetate (4 mL), stirred at room temperature for 4 hours, after completion of the reaction, the reaction solution was concentrated under reduced pressure, 20mL of saturated sodium bicarbonate solution was added, extracted with ethyl acetate (20 mL. Times.3), the saturated sodium chloride solution (20 mL) was washed, the organic phase was dried over anhydrous sodium sulfate, filtered and the resulting residue concentrated under reduced pressure was purified by silica gel column chromatography (eluent: B system) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) imidazolin-2-one 9a (200 mg), yield: 47.93%.
MS m/z(ESI):666.3[M+1] +
Second step
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3- (2-fluoroethyl) -4- (4- (((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 9a (80 mg, 120.16. Mu. Mol) in N, N-dimethylformamide (2 mL) was added sodium hydride (6.25 mg, 144.19. Mu. Mol,60% purity), stirred for 20 minutes, 1-fluoro-2-iodoethane (25.08 mg, 144.19. Mu. Mol) was added and stirred at room temperature for 2 hours, after the end of the reaction, the reaction mixture was quenched with 20mL of ice water, extracted with ethyl acetate (20 mL. Times.3), washed with saturated sodium chloride solution (20 mL), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3- (2-fluoroethyl) -4- (4- (((4- (morpholinomethyl) phenyl) ethynyl) imidazolin-2-one) 9b (99.38%) and the following purification was carried out without direct purification.
MS m/z(ESI):712.3[M+1] +
Third step
5-hydroxy-6- ((3- (2-fluoroethyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
Boron trichloride (1 mL) was added to a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3- (2-fluoroethyl) -4- (4- (((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 9b (85 mg, 119.41. Mu. Mol) in methylene chloride (1 mL) under ice-water bath conditions, reacted at room temperature for 5 hours, after completion of the reaction, quenched with methanol (2 mL) and concentrated under reduced pressure to prepare a liquid phase separation (separation column AKZONOBEL Kromasil; 250X 21.2mm I.D.;5 μm,20mL/min; mobile phase A:0.05% TFA+H) 2 O, mobile phase B: CH (CH) 3 CN) to give 5-hydroxy-6- ((3- (2-fluoroethyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one 9 (4.4 mg), yield: 5.51%.
MS m/z(ESI):532.2[M+1] +
1 H NMR(400MHz,DMSO-d 6 )δ10.30(s,1H),9.51(s,1H),7.78(s,1H),7.66(d,J＝7.9Hz,2H),7.52-7.63(m,4H),7.46(d,J＝8.0Hz,2H),4.77(dd,J＝9.1,7.0Hz,1H),4.21-4.50(m,6H),3.95(s,2H),3.77(t,J＝9.0Hz,2H),3.67(s,2H),3.22(s,2H),3.13(dd,J＝8.9,6.9Hz,3H),2.91(dddd,J＝25.0,15.0,6.4,3.5Hz,1H).
Example 10
5-hydroxy-6- ((3-methyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-methyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 9a (80 mg, 120.16. Mu. Mol) in N, N-dimethylformamide (2 mL) was added sodium hydride (6.25 mg, 144.19. Mu. Mol,60% purity), stirred for 20 min, methyl iodide (20.47 mg, 144.19. Mu. Mol) was added, stirred at room temperature for 2 h, after the end of the reaction, the reaction mixture was quenched with 20mL of ice water, extracted with ethyl acetate (20 mL. Times.3), the saturated sodium chloride solution (20 mL) was washed, the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-methyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 10a (81 mg), yield: 99.16%, without purification, the next reaction was directly carried out.
MS m/z(ESI):680.3[M+1] +
Second step
5-hydroxy-6- ((3-methyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
Boron trichloride (1 mL) was added to a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-methyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 10a (81 mg,119.15 μmol) in dichloromethane (1 mL) under ice-water bath conditions and reacted overnight at room temperature. After completion of the reaction, quenched with methanol (2 mL), concentrated under reduced pressure to give a liquid phase separation (separation column AKZONOBEL Kromasil; 250X 21.2mm I.D.;5 μm,20mL/min; mobile phase A:0.05% TFA+H) 2 O, mobile phase B: CH (CH) 3 CN) to give 5-hydroxy-6- ((3-methyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one 10 (4.38 mg), yield: 5.87%.
MS m/z(ESI):500.2[M+1] +
1 H NMR(400MHz,DMSO-d 6 )δ10.52(s,1H),9.51(s,1H),7.79(s,1H),7.66(d,J＝8.0Hz,2H),7.60(p,J＝4.9,4.4Hz,4H),7.44(d,J＝8.0Hz,2H),4.53(t,J＝8.4Hz,1H),4.39(s,2H),4.25(s,2H),3.83-4.15(m,4H),3.72(s,1H),3.70(s,3H),3.20(d,J＝23.5Hz,4H),3.06(t,J＝8.3Hz,1H).
Example 11
5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 9a (70 mg, 105.14. Mu. Mol) in N, N-dimethylformamide (2 mL) was added sodium hydride (5.47 mg, 126.17. Mu. Mol,60% purity), stirred under ice bath for 20 minutes, 2-iodopropane (19.66 mg, 115.65. Mu. Mol) was further added, stirred at room temperature for 2 hours, after completion of the reaction, 20mL of ice water was added to quench the reaction solution, extracted with ethyl acetate (20 mL. Times.3), washed with saturated sodium chloride solution (20 mL), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) imidazolin-2-one (74 mg) yield: 99.43%, without purification, the next reaction was directly carried out.
MS m/z(ESI):708.3[M+1] +
Second step
5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
Boron trichloride (1.5 mL) was added to 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazoline under ice-water bath conditions2-Ketone 11a (74 mg, 104.54. Mu. Mol) in dichloromethane (1 mL) was reacted overnight at room temperature, after completion of the reaction, quenched with methanol (2 mL), concentrated under reduced pressure to give a liquid phase separation (separation column AKZONOBEL Kromasil; 250X 21.2mM I.D.;5 μm,20mL/min; mobile phase A:0.05% TFA+H) 2 O, mobile phase B: CH (CH) 3 CN) to give 5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one 11 (1.36 mg), yield: 1.95%.
MS m/z(ESI):528.2[M+1] +
1 H NMR(400MHz,Methanol-d 4 )δ7.79(s,1H),7.65(d,J＝8.0Hz,2H),7.52-7.59(m,4H),7.49(d,J＝8.3Hz,2H),4.93-4.94(m,1H),4.79(q,J＝2.3Hz,1H),4.35-4.43(m,3H),4.05(s,2H),3.77-3.89(m,2H),3.75(d,J＝14.2Hz,2H),3.36(d,J＝9.6Hz,2H),3.24(dd,J＝15.7,6.0Hz,2H),3.17-3.21(m,1H),1.23(d,J＝6.8Hz,3H),0.89(d,J＝6.8Hz,3H).
Example 12
5-hydroxy-6- ((3- (2-hydroxyethyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
1- ((5- (benzyloxy) -6-hydroxypyrimidin-4-yl) methyl) -3- (2-hydroxyethyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one
Cesium carbonate (101.0 mg,310.0 μmol) and 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 9a (70 mg,105.14 μmol) were added to N, N-dimethylformamide (2 mL), 2-iodoethanol (19.89 mg,115.65 μmol) was then added, the reaction was heated to 120 ℃ for 3 hours, after completion of the reaction, extracted with ethyl acetate (20 ml×3), washed with water (20 mL) and saturated sodium chloride solution (20 mL), respectively, the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give 1- ((5- (benzyloxy) -6-hydroxypyrimidin-4-yl) methyl) -3- (2-hydroxyethyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) imidazolin-2-one 12a (65 mg) in yield: 99.76%, and the next reaction was directly carried out without purification.
MS m/z(ESI):620.3[M+1] +
Second step
5-hydroxy-6- ((3- (2-hydroxyethyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
Boron trichloride (1.5 mL) was added to 1- ((5- (benzyloxy) -6-hydroxypyrimidin-4-yl) methyl) -3- (2-hydroxyethyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 12a (20 mg, 32.27. Mu. Mol) in dichloromethane (1 mL) under ice-water bath conditions, reacted at room temperature for 5 hours, after completion of the reaction, quenched with methanol (2 mL), concentrated under reduced pressure, and a liquid phase separation (separation column AKZONOBEL Kromasil; 250X 21.2mm I.D.;5 μm,20mL/min; mobile phase A:0.05% TFA+H) was prepared 2 O, mobile phase B: CH (CH) 3 CN) to give 5-hydroxy-6- ((3- (2-hydroxyethyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one 12 (9.53 mg), yield: 43.49%.
MS m/z(ESI):530.2[M+1] +
1 H NMR(400MHz,Methanol-d 4 )δ7.76(s,1H),7.65(d,J＝7.9Hz,2H),7.54(dd,J＝8.2,3.7Hz,4H),7.41-7.47(m,2H),4.95-4.92(m,2H),4.39(d,J＝2.4Hz,4H),3.99-4.15(m,3H),3.92(t,J＝9.1Hz,2H),3.66-3.82(m,3H),3.37(s,2H),3.20-3.29(m,3H).
Example 13 and example 14
(R)-5-hydroxy-6-((3-isopropyl-4-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one 13
(R) -5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one 13
(S)-5-hydroxy-6-((3-isopropyl-4-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)-2-oxoimidaz olidin-1-yl)methyl)pyrimidin-4(3H)-one 14
(S) -5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one 14
First step
5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one 11 (412 MG) was purified by preparative supercritical fluid chromatography (model: MG II preparation SFC (SFC-14), column: chiralCel OX (250X 30mm I.D.,10 μm), mobile phase: A phase CO 2 Phase B was Ethanol (0.1% NH) 3 H 2 O), gradient: phase B40%, flow rate: 80mL/min, backpressure: 100bar, column temperature: 38 c) and the separated fractions were subjected to separation and purification by rotary evaporator and the solvent was removed at a bath temperature of 40 c to give (R) -5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one 13 (114 mg,215 μmol,27.6% yield) and (S) -5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one 14 (122 mg,28.6% yield).
13MS m/z(ESI):528.0[M+1] +
1 H NMR(400MHz,DMSO-d 6 )δ7.78(s,1H),7.64–7.41(m,6H),7.36(d,J＝8.0Hz,2H),4.70(dd,J＝9.2,7.2Hz,1H),4.26(d,J＝15.6Hz,1H),4.19(d,J＝15.2Hz,1H),3.74–3.66(m,2H),3.59–3.57(m,4H),3.49(s,2H),3.04(t,J＝8.0Hz,1H),2.35(t,J＝4.7Hz,4H),1.13(d,J＝6.8Hz,3H),0.77(d,J＝7.2Hz,3H).
14MS m/z(ESI):528.0[M+1] +
Example 15
5-hydroxy-6-((3-isopropyl-2-oxo-4-(4-((4-(((tetrahydrofuran-3-yl)amino)methyl)phenyl)ethynyl)phenyl)imidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-2-oxo-4- (4- ((4- (((tetrahydrofuran-3-yl) amino) methyl) phenyl) ethynyl) phenyl) imidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-isopropyl-4-(4-((4-(((tetrahydrofuran-3-yl)amino)methyl)phenyl)ethynyl)phenyl)imidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- (((tetrahydrofuran-3-yl) amino) methyl) phenyl) ethynyl) phenyl) imidazolin-2-one
4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzaldehyde 4e (50 mg, 78.53. Mu. Mol), tetrahydrofuran-3-amine 15b (13.68 mg, 157.05. Mu. Mol) was dissolved in 1, 2-dichloroethane (5 mL), acetic acid (0.2 mL) was added, stirring was continued for 30 min, sodium borohydride acetate (49.93 mg, 235.58. Mu. Mol) was added, and stirring was continued at room temperature for 12 h. 15mL of saturated aqueous sodium bicarbonate solution was added to quench, dichloromethane (30 mL) and water (15 mL) were added, the solution was separated, the aqueous phase was extracted with dichloromethane (30 mL. Times.2), the combined organic phases were washed with saturated aqueous sodium chloride (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated to dryness under reduced pressure, and the residue was purified by preparative liquid chromatography to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- (((tetrahydrofuran-3-yl) amino) methyl) phenyl) ethynyl) phenyl) imidazolin-2-one 15c (40 mg,71.96% yieldd).
MS m/z(ESI):708.0[M+1] +
Second step
5-hydroxy-6-((3-isopropyl-2-oxo-4-(4-((4-(((tetrahydrofuran-3-yl)amino)methyl)phenyl)ethynyl)phenyl)imidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-2-oxo-4- (4- ((4- (((tetrahydrofuran-3-yl) amino) methyl) phenyl) ethynyl) phenyl) imidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
Boron trichloride (0.4 mL) was added dropwise to a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- (((tetrahydrofuran-3-yl) amino) methyl) phenyl) ethynyl) phenyl) imidazolin-2-one 15c (40 mg,56.51 μmol) in dichloromethane (1 mL) under ice bath conditions, and the reaction was quenched with methanol at room temperature for 2 hours. Preparation of liquid chromatography purification yielded 5-hydroxy-6- ((3-isopropyl-2-oxo-4- (4- ((4- (((tetrahydrofuran-3-yl) amino) methyl) phenyl) ethynyl) phenyl) imidazolin-1-yl) methyl) pyrimidin-4 (3H) -one 15 (6 mg,15.14% yieldd, 91.5% purity).
MS m/z(ESI)：528.0[M+1] +
Example 16
5-hydroxy-6-((3-isopropyl-4-(4-((4-((3-methoxyazetidin-1-yl)methyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-4- (4- ((4- ((3-methoxyazetidin-1-yl) methyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidinyl 4 (3H) -one
First step
3-methoxy-1-(4-((trimethylsilyl)ethynyl)benzyl)azetidine
3-methoxy-1- (4- ((trimethylsilyl) ethynyl) benzyl) azetidine
After 4- (2-trimethylsilylethynyl) benzaldehyde 16a (400 mg,1.98 mmol) was dissolved in 1, 2-dichloroethane (10 mL), 3-methoxyazetidine hydrochloride 16b (488.65 mg,3.95mmol, and acetic acid (1.2 mL) were added, reacted at room temperature for 30 minutes, sodium triacetoxyborohydride (1.26 g,5.93 mmol) was added at 0℃and reacted at room temperature for 2 hours, 50mL of saturated sodium bicarbonate solution was added to the reaction solution, dichloromethane (100 mL) was extracted, the organic phase was dried over anhydrous sodium sulfate, concentrated under reduced pressure, and the residue was further separated and purified by silica gel column chromatography (eluent: system A) to give 3-methoxy-1- (4- ((trimethylsilyl) ethynyl) benzyl) azetidine 16c (mg, 73.99% yield).
MS m/z(ESI)：274.0[M+1] +
Second step
1-(4-ethynylbenzyl)-3-methoxyazetidine
1- (4-ethynylbenzyl) -3-methoxyazetidine
3-methoxy-1- (4- ((trimethylsilyl) ethynyl) benzyl) azetidine 16c (400 mg,1.46 mmol) was added to methanol (10 mL), potassium fluoride (339.96 mg,5.85 mmol) was added, and the reaction was carried out at room temperature for 4 hours. After completion of the reaction, the residue obtained was purified by silica gel column chromatography (eluent: system A) to give 1- (4-ethynylbenzyl) -3-3-methoxyazetidine 16d (280 mg,95.10% yield).
MS m/z(ESI)：202.0[M+1] +
Third step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-isopropyl-4-(4-((4-((3-methoxyazetidin-1-yl)methyl)phenyl)ethynyl)phenyl)imidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- ((3-methoxyazetidin-1-yl) methyl) phenyl) ethynyl) phenyl) imidazolin-2-one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -3-isopropylimidazolin-2-one 16e (55 mg, 86.68. Mu. Mol) and 1- (4-ethynylbenzyl) -3-3-methoxyazetidine 16d (34.9 mg, 173. Mu. Mol) in water (1 mL) was added bis (triphenylphosphine) palladium chloride (2.43 mg, 3.47. Mu. Mol), tetrabutylammonium bromide (27.94 mg, 86.68. Mu. Mol) and piperidine (22.14 mg, 260.04. Mu. Mol) in this order, and the mixture was stirred at 70℃for 5 hours. The reaction solution was extracted with ethyl acetate (30 mL x 2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL x 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system B) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- ((3-methoxyazetidin-1-yl) methyl) phenyl) ethynyl) phenyl) imidazolin-2-one 16f (29 mg,47.26% yield).
MS m/z(ESI)：708.4[M+1] +
Fourth step
5-hydroxy-6-((3-isopropyl-4-(4-((4-((3-methoxyazetidin-1-yl)methyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-4- (4- ((4- ((3-methoxyazetidin-1-yl) methyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidinyl 4 (3H) -one
Boron trichloride (0.8 mL) was added dropwise to a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- ((3-methoxyazetidinyl-1-yl) methyl) phenyl) ethynyl) phenyl) imidazolin-2-one 16f (29 mg, 40.97. Mu. Mol) in dichloromethane (2 mL) at room temperature for 2 hours, quenched with methanol, and purified by preparative liquid chromatography to give 5-hydroxy-6- ((3-isopropyl-4- (4- ((4- ((3-methoxyazetidin-1-yl) methyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one 16 (2 mg,7.55% yield,99.26% purity).
MS m/z(ESI)：528.3[M+1] +
Example 17
5-hydroxy-6-((3-isopropyl-4-(4-((4-(morpholine-4-carbonyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (morpholin-4-carbonyl) phenyl) ethynyl) phenyl) -2-oxoimidazol-1-yl) methyl) pyrimidinyl 4 (3H) -one
First step
(4-ethynylphenyl)(morpholino)methanone
(4-Acetylylphenyl) (morpholinyl) methanone
4-Acetylylbenzoic acid 17a (1 g,6.84 mmol) and morpholine 17b (3.58 g,41.06 mmol) were added to 5mL of dichloromethane, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (2.10 g,10.95 mmol) was added and reacted overnight at room temperature. After completion of the reaction, the reaction mixture was extracted with methylene chloride (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with a saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: system A) to give (4-ethynylphenyl) (morpholinyl) methanone 17c (600 mg,40.74% yield).
MS m/z(ESI)：216.2[M+1] +
Second step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-isopropyl-4-(4-((4-(morpholine-4-carbonyl)phenyl)ethynyl)phenyl)imidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- (morpholine-4-carbonyl) phenyl) ethynyl) phenyl) imidazolin-2-one
To a 1.5mL aqueous solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -3-isopropylimidazolin-2-one 17d and (4-ethynylphenyl) (morpholinyl) methanone 17c (67.85 mg, 315.21. Mu. Mol) were added bis (triphenylphosphine) palladium chloride (4.42 mg, 6.30. Mu. Mol), tetrabutylammonium bromide (50.81 mg, 157.60. Mu. Mol) and piperidine (40.26 mg, 472.81. Mu. Mol) at room temperature, and the reaction was warmed to 70℃and stirred for 5 hours. After completion of the reaction, the reaction mixture was extracted with ethyl acetate (30 mL x 2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL x 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system B) to give 1- ((5, 6-di (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- (morpholine-4-carbonyl) phenyl) ethynyl) phenyl) imidazolin-2-one 17e (100 mg,87.90% yield).
MS m/z(ESI)：722.0[M+1] +
Third step
5-hydroxy-6-((3-isopropyl-4-(4-((4-(morpholine-4-carbonyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (morpholine-4-carbonyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidinyl 4 (3H) -one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- (morpholine-4-carbonyl) phenyl) ethynyl) phenyl) imidazolin-2-one 17e (99.86 mg,138.35 μmol) was added to dichloromethane (5 mL), boron trichloride (2 mL) was added and reacted at room temperature for 1 hour. The reaction was complete, concentrated under reduced pressure, and the prepared liquid phase was separated and purified to give 5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (morpholine-4-carbonyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidinyl 4 (3H) -one 17 (23 mg,24.57% yield,96.88% purity).
MS m/z(ESI)：542.3[M+1] +
Example 20
5-hydroxy-6-((4-methyl-4-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)-2-oxopyrrolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((4-methyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxopyrrolidin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
methyl(E)-3-(4-iodophenyl)but-2-enoate
(E) -3- (4-iodophenyl) but-2-enoic acid methyl ester
To a solution of sodium hydride (1.32 g,30.48mmol,60% purity) in tetrahydrofuran (60 mL) was slowly added dropwise methyl 2- (ethoxyphosphoryl) acetate 20b (6.11 g,33.53 mmol) at 0℃and warmed to room temperature, a solution of 1- (4-iodophenyl) ethanone 20a (5 g,20.32 mmol) in tetrahydrofuran (20 mL) was added dropwise and the reaction was completed at room temperature for 16 hours by LC-MS detection. The reaction mixture was quenched with 60mL of water, extracted with ethyl acetate (30 mL. Times.3), the combined organic phases were successively washed with saturated brine, dried over anhydrous sodium sulfate, and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system A) to give methyl (E) -3- (4-iodophenyl) but-2-enoate 20c (2.8 g,9.27mmol,45.61% yield).
MS m/z(ESI)：303.0[M+1] +
Second step
methyl 3-(4-iodophenyl)-3-methyl-4-nitrobutanoate
3- (4-iodophenyl) -3-methyl-4-nitrobutanoic acid methyl ester
To methyl (E) -3- (4-iodophenyl) but-2-enoate 20c (1.7 g,5.63 mmol) in nitromethane (20 mL) was added tetrabutylammonium fluoride (1M, 5.63 mL) dropwise and the reaction was allowed to proceed overnight at 100℃and was detected by LC-MS. The reaction solution was concentrated under reduced pressure, 12mL of ethyl acetate was added, and the system was acidified with 1M hydrochloric acid solution. Extraction with ethyl acetate (30 mL. Times.3), washing the combined organic phases with saturated brine, drying over anhydrous sodium sulfate, and filtration, the resulting residue was further separated and purified by silica gel column chromatography (eluent: system A) to give methyl 3- (4-iodophenyl) -3-methyl-4-nitrobutanoate 20d (800 mg,2.20mmol,39.15% yield).
MS m/z(ESI)：361.8[M-1] +
Third step
4-(4-iodophenyl)-4-methylpyrrolidin-2-one
4- (4-iodophenyl) -4-methylpyrrolidin-2-one
Methyl 3- (4-iodophenyl) -3-methyl-4-nitrobutanoate 20d (100 mg, 275.37. Mu. Mol) was added to 1mL of methanol, nickel (II) chloride hexahydrate (17.84 mg, 137.69. Mu. Mol) was added, and after 5 minutes of reaction, sodium borohydride (20.83 mg, 550.74. Mu. Mol) was added at 0℃and the reaction was continued overnight at room temperature. Saturated ammonium chloride solution was added at 0deg.C, followed by extraction with dichloromethane (30 mL x 2), the aqueous layer was separated, the combined organic phases were successively washed with saturated sodium chloride solution (30 mL x 2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system A) to give 4- (4-iodophenyl) -4-methylpyrrolidin-2-one 20e (40 mg, 132.84. Mu. Mol,48.24% yield).
MS m/z(ESI)：301.8[M+1] +
Fourth step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-4-(4-iodophenyl)-4-methylpyrrolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -4-methylpyrrolidin-2-one
4- (4-iodophenyl) -4-methylpyrrolidin-2-one 20e (137 mg, 454.96. Mu. Mol) was added to 5mL of acetonitrile, 4, 5-dibenzyloxy-6- (iodomethyl) pyrimidine 20f (196.66 mg, 454.96. Mu. Mol) and cesium carbonate (370.59 mg,1.14 mmol) were sequentially added, and the reaction solution was heated to 90℃to react for 4 hours. The reaction solution was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were successively washed with supersaturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system A and system B) to give 20g (130 mg, 214.71. Mu. Mol,47.19% yieldof 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -4-methylpyrrolidin-2-one.
MS m/z(ESI)：606.1[M+1] +
Fifth step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-4-methyl-4-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)pyrrolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4-methyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) pyrrolidin-2-one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -4-methylpyrrolidin-2-one 20g (80 mg, 132.13. Mu. Mol) and 4- (4-ethynylbenzyl) morpholine 20h (26.6 mg,132. Mu. Mol) in 1mL of water at room temperature was added successively bis triphenylphosphine palladium dichloride (3.71 mg, 5.29. Mu. Mol) tetrabutylammonium bromide (42.59 mg, 132.13. Mu. Mol), piperidine (33.75 mg, 396.39. Mu. Mol). The reaction was warmed to 70 ℃ and stirred for 5 hours. The reaction solution was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system B) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4-methyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) pyrrolidin-2-one 20j (50 mg, 73.66. Mu. Mol,55.75% yield).
MS m/z(ESI)：679.0[M+1] +
Sixth step
5-hydroxy-6-((4-methyl-4-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)-2-oxopyrrolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((4-methyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxopyrrolidin-1-yl) methyl) pyrimidin-4 (3H) -one
Boron trichloride (0.8 mL) was added dropwise to a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4-methyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) pyrrolidin-2-one 20j (50 mg, 73.66. Mu. Mol) in 2mL of dichloromethane at room temperature, reacted for 2 hours, quenched with methanol, concentrated under reduced pressure, and the residue was purified by preparative liquid phase separation to give 5-hydroxy-6- ((4-methyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxopyrrolidin-1-yl) methyl) pyrimidin-4 (3H) -one 20 (10 mg, 15.12. Mu. Mol,20.52% yield, 92.6%)
MS m/z(ESI)：499.2[M+1] +
Example 21
6-((4-(4-((4-(((1,1-dioxidotetrahydrothiophen-3-yl)amino)methyl)phenyl)ethynyl)phenyl)-3-isopropyl-2-oxoimidazolidin-1-yl)methyl)-5-hydroxypyrimidin-4(3H)-one
6- ((4- (4- ((4- (((1, 1-tetrahydroxythiophen-3-yl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazolin-1-yl) methyl) -5-hydroxypyrimidin-4 (3H) -one
First step
tert-butyl
3-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-5-(4-iodophenyl)-2-oxoimidazolidine-1-carboxylate
3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4-iodophenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester
5- (4-iodophenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester 21a (4.2 g,10.82 mmol), 4, 5-dibenzyloxy-6- (iodomethyl) pyrimidine 21b (4.68 g,10.82 mmol), potassium carbonate (4.49 g,32.46 mmol) were added to 70mL of acetonitrile, and the reaction solution was heated to 98℃and refluxed overnight, and the reaction was monitored to completion. Water (20 mL) was added to the reaction solution, ethyl acetate was extracted (30 mL. Times.3), the combined organic phases were washed successively with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system A) to give tert-butyl 3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4-iodophenyl) -2-oxoimidazoline-1-carboxylate 21c (3 g,4.33mmol,40.04% yield).
MS m/z(ESI):592.8[M-100+H]
Second step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-4-(4-iodophenyl)imidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) imidazolin-2-one
A solution of 3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4-iodophenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester 21c (1.5 g,2.17 mmol) in 1, 4-dioxane (20 mL) was added dropwise to a solution of 1, 4-dioxane in hydrochloric acid (4M, 10.83 mL) under ice, the ice was removed, the reaction was monitored for completion at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, 30mL of saturated sodium bicarbonate solution was added to the residue, ethyl acetate was used for extraction (30 mL. Times.3), the combined organic phases were washed successively with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: system B) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) imidazolin-2-one 21d (1 g,1.69mmol,77.93% yield).
MS m/z(ESI)：592.8[M+1] +
Third step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-4-(4-iodophenyl)-3-isopropylimidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -3-isopropylimidazolin-2-one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) imidazolin-2-one 21d (1 g,1.69 mmol) in N, N-dimethylformamide (30 mL) under argon was added sodium hydride (146.35 mg,3.38mmol,60% purity) under an ice bath, and after stirring for 20 minutes under an ice bath, 2-iodopropane (573.88 mg,3.38mmol, 336.98. Mu.L) was added and stirring was carried out at room temperature for 2 hours, and the reaction was monitored to completion. To the reaction solution was added 20mL of ice water, extracted with ethyl acetate (20 mL. Times.3), the combined organic phases were washed successively with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system A) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -3-isopropylimidazolin-2-one 21e (450 mg, 709.21. Mu. Mol,42.02% yieldd).
MS m/z(ESI):634.8[M+1]
Fourth step
3-((4-((trimethylsilyl)ethynyl)benzyl)amino)tetrahydrothiophene 1,1-dioxide
3- ((4- ((trimethylsilyl) ethynyl) phenyl) amino) tetrahydrothiophene 1, 1-dioxide
After 4- (2-trimethylsilylethynyl) benzaldehyde 21f (400 mg,1.98 mmol) was dissolved in 1, 2-dichloroethane (20L), 21g (678.70 mg,3.95 mmol) of 1, 1-dioxotetrahydrothiophene-3-amine hydrochloride and acetic acid (1.25 mL) were added, and after 30 minutes at room temperature, sodium triacetoxyborohydride (1.26 g,5.93 mmol) was added and reacted at 0℃for 2 hours at room temperature. The reaction was added 50mL of saturated sodium bicarbonate solution, extracted with dichloromethane (100 mL), the combined organic phases dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was further isolated and purified by silica gel column chromatography (eluent: system B) to give 3- ((4- ((trimethylsilyl) ethynyl) phenyl) amino) tetrahydrothiophene 1, 1-dioxide 21h (290 mg, 902.00. Mu. Mol,45.62% yield).
MS m/z(ESI)：321.9[M+1] +
Fifth step
3-((4-ethynylbenzyl)amino)tetrahydrothiophene 1,1-dioxide
3- ((4-ethynylbenzyl) amino) tetrahydrothiophene 1, 1-dioxide
To a solution of 3- ((4- ((trimethylsilyl) ethynyl) phenyl) amino) tetrahydrothiophene 1, 1-dioxide 21h (280 mg, 870.89. Mu. Mol) in 30mL methanol was added potassium fluoride (202.40 mg,3.48 mmol) and reacted at room temperature for 4 hours. The reaction solution was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system B) to give 3- ((4-ethynylbenzyl) amino) tetrahydrothiophene 1, 1-dioxide 21j (180 mg, 721.94. Mu. Mol,82.90% yieldd).
MS m/z(ESI)：250.0[M+1] +
Sixth step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-4-(4-((4-(((1,1-dioxidotetrahydrothiophen-3-yl)amino)methyl)phenyl)ethynyl)phenyl)-3-isopropylimidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (((1, 1-dioxotetrahydrothiophen-3-yl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -3-isopropylimidazolin-2-one 21e (45 mg, 70.92. Mu. Mol) and 3- ((4-ethynylbenzyl) amino) tetrahydrothiophene 1, 1-dioxide 21j (21.22 mg, 85.11. Mu. Mol) in water (1 mL) at room temperature was added bis triphenylphosphine palladium dichloride (1.99 mg, 2.84. Mu. Mol), tetrabutylammonium bromide (22.86 mg, 70.92. Mu. Mol) and piperidine (18.12 mg, 212.76. Mu. Mol) in this order, and the reaction was warmed to 70℃and stirred for 5 hours. The reaction solution was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system B) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (((1, 1-dioxotetrahydrothiophen-3-yl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one 21k (50 mg, 66.14. Mu. Mol,93.26% yield).
MS m/z(ESI)：755.9[M+1] +
Seventh step
6-((4-(4-((4-(((1,1-dioxidotetrahydrothiophen-3-yl)amino)methyl)phenyl)ethynyl)phenyl)-3-isopropyl-2-oxoimidazolidin-1-yl)methyl)-5-hydroxypyrimidin-4(3H)-one
6- ((4- (4- ((4- (((1, 1-tetrahydroxythiophen-3-yl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazolin-1-yl) methyl) -5-hydroxypyrimidin-4 (3H) -one
Boron trichloride (0.8 mL) was added dropwise to a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (((1, 1-dioxotetrahydrothiophen-3-yl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one 21k (60 mg, 79.37. Mu. Mol) in dichloromethane (2 mL) under ice bath, reacted for 2 hours at room temperature, quenched with methanol, concentrated under reduced pressure, and the residue was purified by preparative liquid phase separation to give 6- ((4- (((1, 1-tetrahydrothiophen-3-yl) amino) methyl) phenyl) ethynyl) -3-isopropyl-2-oxoimidazolin-1-yl) methyl) -5-hydroxypyrimidinyl-4 (3H) -one 21 (2 mg, 2.81. Mu. Mol,3.54% yieldd).
MS m/z(ESI)：575.9[M+1] +
Example 22
6-((4-(4-((4-((1,1-dioxidothiomorpholino)methyl)phenyl)ethynyl)phenyl)-3-isopropyl-2-oxoimidazolidin-1-yl)methyl)-5-hydroxypyrimidin-4(3H)-one
6- ((4- (4- ((4- ((1, 1-thiomorpholino) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazol-1-yl) methyl) -5-hydroxypyrimidin-4 (3H) -one
First step
4-(4-((trimethylsilyl)ethynyl)benzyl)thiomorpholine 1,1-dioxide
4- (4- ((trimethylsilyl) ethynyl) benzyl) thiomorpholine 1, 1-dioxide
4- (2-Trisilylethynyl) benzaldehyde 22a (400 mg,1.98 mmol) was dissolved in 1, 2-dichloroethane (15 mL), thiomorpholine 1, 1-dioxide 22b (534.53 mg,3.95 mmol) and acetic acid (1.25 mL) were added in this order, and after 30 minutes at room temperature, sodium triacetoxyborohydride (1.26 g,5.93 mmol) was added and the reaction was carried out at 0℃for two hours at room temperature. The reaction mixture was taken up in 50mL of saturated sodium bicarbonate solution, extracted with dichloromethane (100 mL), the organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, and the resulting residue was further separated and purified by column chromatography on silica gel (eluent: system A) to give 4- (4- ((trimethylsilyl) ethynyl) benzyl) thiomorpholine 1, 1-dioxide 22c (157 mg, 488.32. Mu. Mol,24.70% yield)
MS m/z(ESI)：321.9[M+1] +
Second step
4-(4-ethynylbenzyl)thiomorpholine 1,1-dioxide
4- (4-ethynylbenzyl) thiomorpholine 1, 1-dioxide
4- (4- ((trimethylsilyl) ethynyl) benzyl) thiomorpholine 1, 1-dioxide 22c (157 mg, 488.32. Mu. Mol) was added to methanol (5 mL), potassium fluoride (113.49 mg,1.95 mmol) was added and reacted at room temperature for 4 hours. After completion of the reaction, the resulting residue was purified by silica gel column chromatography (eluent: system A) to give 4- (4-ethynylbenzyl) thiomorpholine 1, 1-dioxide 22d (90 mg, 360.97. Mu. Mol,73.92% yield).
MS m/z(ESI)：249.9[M+1] +
Third step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-4-(4-((4-((1,1-dioxidothiomorpholino)methyl)phenyl)ethynyl)phenyl)-3-isopropylimidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- ((1, 1-thiomorpholino) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -3-isopropylimidazolin-2-one 21e (45 mg, 70.92. Mu. Mol) and 4- (4-ethynylbenzyl) thiomorpholine 1, 1-dioxide 22d (21.22 mg, 85.11. Mu. Mol) in water (1 mL) at room temperature was added bis triphenylphosphine palladium dichloride (1.99 mg, 2.84. Mu. Mol), tetrabutylammonium bromide (22.86 mg, 70.92. Mu. Mol) and piperidine (18.12 mg, 212.76. Mu. Mol) in this order, and the mixture was stirred at 70℃for 5 hours. The reaction solution was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system B) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- ((1, 1-thiomorpholinomethyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one 22e (26 mg, 34.40. Mu. Mol,48.50% yieldd).
MS m/z(ESI)：755.9[M+1] +
Fourth step
6-((4-(4-((4-((1,1-dioxidothiomorpholino)methyl)phenyl)ethynyl)phenyl)-3-isopropyl-2-oxoimidazolidin-1-yl)methyl)-5-hydroxypyrimidin-4(3H)-one
6- ((4- (4- ((4- ((1, 1-thiomorpholino) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazol-1-yl) methyl) -5-hydroxypyrimidin-4 (3H) -one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- ((1, 1-thiomorpholino) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one 22e (26 mg, 34.40. Mu. Mol) in dichloromethane (1 mL) was added dropwise boron trichloride (0.4 mL) under ice bath, reacted for 2 hours at room temperature, quenched with methanol, concentrated under reduced pressure, and the residue was purified by preparative liquid phase separation to give 6- ((4- (4- ((4- ((1, 1-thiomorpholino) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazolin-1-yl) methyl) -5-hydroxypyrimidino-4 (3H) -one 22 (3 mg, 4.11. Mu. Mol,11.96% yield).
MS m/z(ESI)：575.9[M+1] +
Example 23
5-hydroxy-6-((3-isopropyl-2-oxo-4-(4-((4-((tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)methyl)phenyl)ethynyl)phenyl)imidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-2-oxo-4- (4- ((4- ((tetrahydro-1H-furan [3,4-c ] pyrrol-5 (3H) -yl) methyl) phenyl) ethynyl) phenyl) imidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
5-(4-((trimethylsilyl)ethynyl)benzyl)hexahydro-1H-furo[3,4-c]pyrrole
5- (4- ((trimethylsilyl) ethynyl l) benzyl) hexahydro-1H-furo [3,4-c ] pyrrole
4- (2-trimethylsilylethynyl) benzaldehyde 22a (400 mg,1.98 mmol) was dissolved in 1, 2-dichloroethane (20 mL), hexahydro-1H-furo [3,4-c ] pyrrole 23a (335.57 mg,2.97 mmol) and acetic acid (1.25 mL) were added sequentially, and after reacting at room temperature for 2 hours, sodium triacetoxyborohydride (1.26 g,5.93 mmol) was added and reacted at room temperature for 2 hours. The reaction mixture was added with 50mL of saturated sodium bicarbonate solution, extracted with dichloromethane (100 mL), the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was further separated and purified by silica gel column chromatography (eluent: system B) to give 5- (4- ((trimethylsilyl) ethynyl) benzyl) hexahydro-1H-furo [3,4-c ] pyrrole 23B (460 mg,1.54mmol,77.69% yield).
MS m/z(ESI)：300.0[M+1] +
Second step
5-(4-ethynylbenzyl)hexahydro-1H-furo[3,4-c]pyrrole
5- (4-ethynylbenzyl) hexahydro-1H-furo [3,4-c ] pyrrole
To a solution of 5- (4- ((trimethylsilyl) ethynyl) benzyl) hexahydro-1H-furo [3,4-c ] pyrrole 23b (460 mg,1.54 mmol) in methanol (20 mL) was added potassium fluoride (356.96 mg,6.14 mmol) and reacted at room temperature for 4 hours. The reaction solution was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with a saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: system A) to give 5- (4-ethynylbenzyl) hexahydro-1H-furo [3,4-c ] pyrrole 23c (311 mg,1.37mmol,89.08% yieldd).
MS m/z(ESI)：228.0[M+1] +
Third step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-isopropyl-4-(4-((4-((tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)methyl)phenyl)ethynyl)phenyl)imidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- ((tetrahydro-1H-furo [3,4-c ] pyrrol-5 (3H) -yl) methyl) phenyl) ethynyl) phenyl) imidazolin-2-one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -3-isopropylimidazolin-2-one 21e (45.81 mg, 72.20. Mu. Mol) and 5- (4-ethynylbenzyl) hexahydro-1H-furo [3,4-c ] pyrrole 23c (19.7 mg, 87. Mu. Mol) in water (1 mL) at room temperature was added, successively, bis triphenylphosphine palladium dichloride (2.03 mg, 2.89. Mu. Mol), tetrabutylammonium bromide (23.27 mg, 72.20. Mu. Mol) and piperidine (18.44 mg, 216.59. Mu. Mol). The reaction was warmed to 70 ℃ and stirred for 5 hours. The reaction solution was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system B) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- ((tetrahydro-1H-furo [3,4-c ] pyrrol-5 (3H) -yl) methyl) phenyl) ethynyl) phenyl) imidazolin-2-one 23d (45 mg, 61.32. Mu. Mol,84.93% yield).
MS m/z(ESI)：734.0[M+1] +
Fourth step
5-hydroxy-6-((3-isopropyl-2-oxo-4-(4-((4-((tetrahydro-1H-furo[3,4-c]pyrrol-5(3H)-yl)methyl)phenyl)ethynyl)phenyl)imidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-2-oxo-4- (4- ((4- ((tetrahydro-1H-furan [3,4-c ] pyrrol-5 (3H) -yl) methyl) phenyl) ethynyl) phenyl) imidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- ((tetrahydro-1H-furo [3,4-c ] pyrrol-5 (3H) -yl) methyl) phenyl) ethynyl) phenyl) imidazolin-2-one 23d (45 mg, 61.32. Mu. Mol) in dichloromethane (1 mL) was added dropwise boron trichloride (0.4 mL) under ice bath, reacted at room temperature for 2 hours, quenched with methanol, concentrated under reduced pressure, and the residue was purified by preparative liquid phase separation to give 5-hydroxy-6- ((3-isopropyl-2-oxo-4- (4- ((4- ((tetrahydro-1H-furo [3,4-c ] pyrrol-5 (3H) -yl) methyl) phenyl) ethynyl) phenyl) imidazolin-1-yl) methyl) pyrimidin-4 (3H) -one 23 (5 mg, 7.38. Mu. Mol,12.04% yield.
MS m/z(ESI)：554.0[M+1] +
Example 24
5-hydroxy-6-((4-(4-((4-((4-hydroxypiperidin-1-yl)methyl)phenyl)ethynyl)phenyl)-3-isopropyl-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((4- (4- ((4- ((4-hydroxypiperidin-1-yl) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
4-((4-(1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)benzaldehyde
4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzaldehyde
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) imidazolin-2-one 21d (300 mg, 472.81. Mu. Mol) and 4-ethynylbenzaldehyde 24a (73.8 mg, 567. Mu. Mol) in water (1 mL) at room temperature were added 13.27mg of ditriphenylphosphine palladium dichloride, 18.91. Mu. Mol), tetrabutylammonium bromide (152.42 mg, 472.81. Mu. Mol) and piperidine (120.78 mg,1.42 mmol) in this order, and the reaction was warmed to 70℃and stirred for 5 hours. The reaction solution was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system B) to give 4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzaldehyde 24B (230 mg, 361.22. Mu. Mol,76.40% yield).
MS m/z(ESI)：637.3[M+1] +
Second step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-4-(4-((4-((4-hydroxypiperidin-1-yl)methyl)phenyl)ethynyl)phenyl)-3-isopropylimidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- ((4-hydroxypiperidin-1-yl) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one
4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazol-4-yl) phenyl) ethynyl) benzaldehyde 24b (50 mg, 78.53. Mu. Mol), piperidin-4-ol (15.89 mg, 157.05. Mu. Mol) was dissolved in 5mL of 1, 2-dichloroethane, acetic acid (0.2 mL) was added, stirring was performed for 30 min, sodium borohydride acetate (49.93 mg, 235.58. Mu. Mol) was added, and stirring was continued at room temperature for 12 h. 15mL of saturated aqueous sodium bicarbonate solution was added to quench, dichloromethane (30 mL) and water (15 mL) were added, the solution was separated, the aqueous phase was extracted with dichloromethane (30 mL. Times.2), the combined organic phases were washed with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system B) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- ((4-hydroxypiperidin-1-yl) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one 24c (20 mg, 27.71. Mu. Mol,35.28% yield).
MS m/z(ESI)：722.0[M+1] +
Third step
5-hydroxy-6-((4-(4-((4-((4-hydroxypiperidin-1-yl)methyl)phenyl)ethynyl)phenyl)-3-isopropyl-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((4- (4- ((4- ((4-hydroxypiperidin-1-yl) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- ((4-hydroxypiperidin-1-yl) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one 24c (20 mg, 27.71. Mu. Mol) in dichloromethane (2 mL) in an ice bath was added dropwise boron trichloride (0.8 mL), reacted at room temperature for 2 hours, quenched with methanol, concentrated under reduced pressure, and the residue was purified by preparative liquid phase separation to give 5-hydroxy-6- ((4- (4- ((4- ((4-hydroxypiperidin-1-yl) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one 24 (1 mg, 1.41. Mu. Mol,5.08% yield).
MS m/z(ESI)：542.0[M+1] +
Example 25
5-hydroxy-6-((3-isopropyl-4-(4-((6-(morpholinomethyl)pyridin-3-yl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-4- (4- ((6- (morpholinomethyl) pyridin-3-yl) ethynyl) phenyl) -2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one
First step
4-((5-ethynylpyridin-2-yl)methyl)morpholine
4- ((5-ethynylpyridin-2-yl) methyl) morpholine
5-Acetylylpyridine-2-carbaldehyde 25a (200 mg,1.53 mmol) was dissolved in 1, 2-dichloroethane (3 mL), and morpholine 25b (398.62 mg,4.58 mmol), acetic acid (0.2 mL) and sodium borohydride acetate (969.75 mg,4.58 mmol) were added in this order and reacted at room temperature for 4 hours. The reaction was quenched with water at 0deg.C, extracted with dichloromethane (30 ml×2), the aqueous layer was separated, the combined organic phases were washed sequentially with saturated sodium chloride solution (30 ml×2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system A) to give 4- ((5-ethynylpyridin-2-yl) methyl) morpholine 25c (170 mg, 840.54. Mu. Mol,55.11% yieldd).
MS m/z(ESI)：203.1[M+1] +
Second step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-isopropyl-4-(4-((6-(morpholinomethyl)pyridin-3-yl)ethynyl)phenyl)imidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((6- (morpholinomethyl) pyridin-3-yl) ethynyl) phenyl) imidazolin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -3-isopropylimidazolin-2-one 21e (50 mg, 78.80. Mu. Mol) and 4- ((5-ethynylpyridin-2-yl) methyl) morpholine 25c (19.13 mg, 94.56. Mu. Mol) were added to a solution of bis triphenylphosphine palladium dichloride (2.21 mg, 3.15. Mu. Mol), tetrabutylammonium bromide (25.40 mg, 78.80. Mu. Mol) and piperidine (20.13 mg, 236.40. Mu. Mol) in this order at room temperature, and the reaction was warmed to 70℃and stirred for 5 hours. The reaction solution was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system B) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((6- (morpholinomethyl) pyridin-3-yl) ethynyl) phenyl) imidazolin-2-one 25d (55 mg, 77.59. Mu. Mol,98.46% yield).
MS m/z(ESI)：709.3[M+1] +
Third step
5-hydroxy-6-((3-isopropyl-4-(4-((6-(morpholinomethyl)pyridin-3-yl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-4- (4- ((6- (morpholinomethyl) pyridin-3-yl) ethynyl) phenyl) -2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((6- (morpholinomethyl) pyridin-3-yl) ethynyl) phenyl) imidazolin-2-one 25d (50 mg, 70.54. Mu. Mol) in dichloromethane (2 mL) was added dropwise boron trichloride (0.8 mL) under ice bath, reacted at room temperature for 2 hours, quenched with methanol, concentrated under reduced pressure, and the residue was purified by preparative liquid phase separation to give 5-hydroxy-6- ((3-isopropyl-4- (4- ((6- (morpholinomethyl) pyridin-3-yl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidinyl-4 (3H) -one 25 (10 mg, 14.83. Mu. Mol,21.03% yield).
MS m/z(ESI)：529.0[M+1] +
Example 26
6-((3-cyclopropyl-4-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)-5-hydroxypyrimidin-4(3H)-one
6- ((3-cyclopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) -5-hydroxypyrimidin-4 (3H) -one
First step
tert-butyl
3-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-5-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidine-1-carboxylate
3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester
3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4-iodophenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester 21c (4 g,5.78 mmol), 4- (4-ethynylbenzyl) morpholine 26a (1.39 g,6.93 mmol), bis triphenylphosphine palladium dichloride (203 mg, 289. Mu. Mol), tetrabutylammonium bromide (1.86 g,5.78 mmol) and piperidine (1.48 g,17.33 mmol) were added to 50mL of water under argon and reacted at 75℃for 5 hours. After completion of the reaction, water (20 mL), ethyl acetate extraction (40 mL. Times.3) and washing of the combined organic phases with saturated sodium chloride solution (20 mL), drying over anhydrous sodium sulfate, filtration and concentration under reduced pressure were added, and the resulting residue was purified by silica gel column chromatography (eluent: system A) to give tert-butyl 3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazoline-1-carboxylate 26b (3 g,3.92mmol,67.8% yield).
MS m/z(ESI):766.5[M+1] +
Second step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-4-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)imidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one
Concentrated hydrochloric acid (3.0 mL) was added to a 30mL solution of 3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazoline-1-carboxylic acid tert-butyl ester 26b (3 g,3.92 mmol) in 30mL of 1, 4-dioxane at room temperature for 2 hours. After completion of the reaction, saturated sodium bicarbonate solution was added to basicity, the organic solvent was removed by concentration under reduced pressure, extraction with ethyl acetate (40 mL. Times.3), washing with saturated sodium chloride solution (20 mL) in this order, drying over anhydrous sodium sulfate, filtration, concentration under reduced pressure, and purification of the resulting residue by silica gel column chromatography (eluent: system B) gave 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 26c (2.34 g,3.51mmol,89.7% yield).
MS m/z(ESI):666.3[M+1] +
Third step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-cyclopropyl-4-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)imidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-cyclopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 26c (200 mg, 300. Mu. Mol) in tetrahydrofuran (1.5 mL) was added cyclopropylboronic acid (77.4 mg, 901. Mu. Mol), copper acetate (164 mg, 901. Mu. Mol) and heated to 80℃for reaction overnight. After completion of the reaction, ethyl acetate (50 mL) was added, the filtrate was washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system A) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-cyclopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 26d (40 mg, 56.7. Mu. Mol,18.9% yieldd).
MS m/z(ESI):706.3[M+1] +
Fourth step
6-((3-cyclopropyl-4-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)-5-hydroxypyrimidin-4(3H)-one
6- ((3-cyclopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) -5-hydroxypyrimidin-4 (3H) -one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-cyclopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 26d (60 mg, 85. Mu. Mol) in dichloromethane (1.2 mL) was added dropwise boron trichloride (2.5 mL) at room temperature for 5 hours under ice bath. After completion of the reaction, quenched with methanol, concentrated under reduced pressure, and the residue was purified by preparative liquid chromatography to give 6- ((3-cyclopropyl-4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazol-1-yl) methyl) -5-hydroxypyrimidin-4 (3H) -one 26 (11.7 mg,18.3 μmol,21.5% yieldd).
MS m/z(ESI):526.2[M+1] +
Example 27
2-(3-((5-hydroxy-6-oxo-1,6-dihydropyrimidin-4-yl)methyl)-5-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)acetonitrile
2- (3- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) acetonitrile
First step
2-(3-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-5-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)acetonitrile
2- (3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) acetonitrile
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 26h (620 mg, 931. Mu. Mol) in 10mL of N, N-dimethylformamide under an argon atmosphere was added sodium hydride (121 mg,2.79mmol,60% purity), and the mixture was allowed to react at room temperature for 20 minutes, and 2-chloroacetonitrile (211 mg,2.79 mmol) was added to continue the reaction for 3 hours. After completion of the reaction, the reaction was quenched by addition of water (20 mL). The combined organic phases were extracted with ethyl acetate (30 mL. Times.3), washed successively with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was purified by column chromatography on silica gel (eluent: system A) to give 2- (3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) acetonitrile 27a (270 mg, 383. Mu. Mol,41.1% yield)
MS m/z(ESI):705.3[M+1] +
Second step
2-(3-((5-hydroxy-6-oxo-1,6-dihydropyrimidin-4-yl)methyl)-5-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)acetonitrile
2- (3- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) acetonitrile
Boron trichloride (3 mL) was added to a solution of 2- (3- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) acetonitrile 27a (130 mg, 184. Mu. Mol) in 1.2mL dichloromethane at room temperature, and stirred for 5 hours. After completion of the reaction, the reaction was quenched with a small amount of ice water, concentrated, and the residue was purified by preparative liquid chromatography to give 2- (3- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) acetonitrile 27 (31.5 mg, 49.0. Mu. Mol,26.6% yield).
MS m/z(ESI):525.3[M+1] +
Example 28
2-(3-((5-hydroxy-6-oxo-1,6-dihydropyrimidin-4-yl)methyl)-5-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)acetamide
2- (3- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) acetamide
Potassium hydroxide (3.21 mg, 57.2. Mu. Mol) was added to a solution of 2- (3- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) acetonitrile 27 (15 mg, 28.6. Mu. Mol) in dimethyl sulfoxide (1 mL) under ice bath, hydrogen peroxide (30%, 0.5 mL) was added dropwise, and the mixture was allowed to react at room temperature for 1 hour. After completion of the reaction, the reaction mixture was neutralized with 1M hydrochloric acid and concentrated under reduced pressure, and the residue was purified by preparative liquid chromatography to give 2- (3- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -5- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) acetamide 28 (13.0 mg, 19.0. Mu. Mol,66.5% yield)
MS m/z(ESI):543.2[M+1] +
Example 29
6-((3-(2,2-difluoroethyl)-4-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)-5-hydroxypyrimidin-4(3H)-one
6- ((3- (2, 2-difluoroethyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazol-1-yl) methyl) -5-hydroxypyrimidin-4 (3H) -one
First step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-(2,2-difluoroethyl)-4-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)imidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3- (2, 2-difluoroethyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one
Sodium hydride (7.81 mg, 180. Mu. Mol,60% purity) was added to a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one (80 mg, 120. Mu. Mol) in N, N-dimethylformamide (2 mL) under an argon atmosphere, and after stirring for 10 minutes, trifluoromethanesulfonic acid (2, 2-difluoroethyl ester) (51.5 mg, 240. Mu. Mol) was added and the reaction was continued for 2 hours. After completion of the reaction, water (20 mL) was added, the organic phases were combined, washed with saturated sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system A) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3- (2, 2-difluoroethyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 29a (80 mg, 110. Mu. Mol,91.2% yield)
MS m/z(ESI):730.3[M+1] +
Second step
6-((3-(2,2-difluoroethyl)-4-(4-((4-(morpholinomethyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)-5-hydroxypyrimidin-4(3H)-one
6- ((3- (2, 2-difluoroethyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazol-1-yl) methyl) -5-hydroxypyrimidin-4 (3H) -one
Boron trichloride (3 mL) was added to a 1.5mL dichloromethane solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3- (2, 2-difluoroethyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 29a (100 mg,137 μmol) and reacted overnight at room temperature. After completion of the reaction, the reaction was quenched with methanol, concentrated under reduced pressure, and the residue was purified by preparative liquid chromatography to give 6- ((3- (2, 2-difluoroethyl) -4- (4- ((4- (morpholinomethyl) phenyl) ethynyl) phenyl) -2-oxoimidazol-1-yl) methyl) -5-hydroxypyrimidin-4 (3H) -one 29 (34.8 mg,50.3 μmol,36.7% yieldd). MS m/z (ESI) 550.3[ M+1 ]] +
Example 30
5-hydroxy-6-((4-(4-((4-(((2-hydroxyethyl)amino)methyl)phenyl)ethynyl)phenyl)-3-isopropyl-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((4- (4- ((4- (((2-hydroxyethyl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one
First step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-4-(4-((4-(((2-hydroxyethyl)amino)methyl)phenyl)ethynyl)phenyl)-3-isopropylimidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (((2-hydroxyethyl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one
24g (62 mg, 97.37. Mu. Mol) of 4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzaldehyde and 30a (11.90 mg, 194.74. Mu. Mol) of 2-aminoethanol were dissolved in 3mL of 1, 2-dichloroethane, acetic acid (1 mL) was added, stirring was carried out at room temperature for 30 minutes, and sodium triacetylborohydride (41.27 mg, 194.74. Mu. Mol) was added, stirring was carried out at room temperature for 12 hours. After completion of the reaction, 15mL of saturated aqueous sodium bicarbonate solution was added, extracted with dichloromethane (30 mL. Times.2), the combined organic phases were washed sequentially with saturated aqueous sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was purified by preparative liquid chromatography (eluent: system B) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (((2-hydroxyethyl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one 30B (25 mg, 36.67. Mu. Mol,37.66% yieldd).
MS m/z(ESI)：682.0[M+1] +
Second step
5-hydroxy-6-((4-(4-((4-(((2-hydroxyethyl)amino)methyl)phenyl)ethynyl)phenyl)-3-isopropyl-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((4- (4- ((4- (((2-hydroxyethyl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (((2-hydroxyethyl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one 30b (25 mg, 36.67. Mu. Mol) was added to 2mL of dichloromethane, boron trichloride (0.8 mL) was added and reacted at room temperature for 2 hours. After completion of the reaction, concentrated under reduced pressure, and the residue was purified by preparative liquid phase separation to give 5-hydroxy-6- ((4- (4- ((4- (((2-hydroxyethyl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one 30 (7 mg,10.81 μmol,29.48% yieldd).
MS m/z(ESI)：502.0[M+1] +
Example 31
2-((4-((4-(1-((5-hydroxy-6-oxo-1,6-dihydropyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)benzyl)amino)acetamide
2- ((4- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) amino) acetamide
First step
2-((4-((4-(1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)benzyl)amino)acetamide
2- ((4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) amino) acetamide
24g (73 mg, 114.65. Mu. Mol) of 4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzaldehyde and 2-aminoacetamide 31a (16.99 mg, 229.29. Mu. Mol) were dissolved in 2mL of 1, 2-dichloroethane, acetic acid (0.5 mL) was added, stirring was continued at room temperature for 30 min, and sodium triacetylborohydride (48.60 mg, 229.29. Mu. Mol) was added, stirring was continued at room temperature for 12 h. After completion of the reaction, 15mL of saturated aqueous sodium bicarbonate solution was added, quenched, dichloromethane (30 mL) and water (15 mL) were added, the aqueous phase was separated, the aqueous phase was extracted with dichloromethane (30 mL. Times.2), the combined organic phases were washed with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was purified by preparative liquid chromatography (eluent: system B) to give 2- ((4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) amino) acetamide 31B (50 mg, 71.96. Mu. Mol,62.77% yield).
MS m/z(ESI)：695.4[M+1] +
Second step
2-((4-((4-(1-((5-hydroxy-6-oxo-1,6-dihydropyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)benzyl)amino)acetamide
2- ((4- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) amino) acetamide
2- ((4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) amino) acetamide 31b (50 mg, 71.96. Mu. Mol) was added to 2mL of dichloromethane, boron trichloride (0.8 mL) was added and reacted at room temperature for 1 hour. After completion of the reaction, concentrated under reduced pressure and the residue purified by preparative liquid phase separation to give 2- ((4- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) amino) acetamide 31 (16 mg, 24.53. Mu. Mol,34.09% yield).
MS m/z(ESI)：515.0[M+1] +
Example 32
5-hydroxy-6-((4-(4-((4-((3-hydroxypyrrolidin-1-yl)methyl)phenyl)ethynyl)phenyl)-3-isopropyl-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((4- (4- ((4- ((3-hydroxypyrrolidin-1-yl) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-4-(4-((4-((3-hydroxypyrrolidin-1-yl)methyl)phenyl)ethynyl)phenyl)-3-isopropylimidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- ((3-hydroxypyrrolidin-1-yl) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one
24g (50 mg, 78.53. Mu. Mol) of 4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzaldehyde and pyrrolidin-3-ol 32a (13.68 mg, 157.05. Mu. Mol) were dissolved in 1mL of 1, 2-dichloroethane, acetic acid (0.2 mL) was added, stirring was continued for 30 minutes, and sodium triacetylborohydride (33.29 mg, 157.05. Mu. Mol) was added and stirring was continued at room temperature for 12 hours. After completion of the reaction, 15mL of saturated aqueous sodium bicarbonate solution was added, quenched, dichloromethane (30 mL) and water (15 mL) were added, the solution was separated, the aqueous phase was extracted with dichloromethane (30 mL. Times.2), the combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by preparative liquid chromatography (eluent: system A) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- ((3-hydroxypyrrolidin-1-yl) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one 32b (40 mg, 56.51. Mu. Mol,71.96% yieldd).
MS m/z(ESI)：708.5[M+1] +
Second step
5-hydroxy-6-((4-(4-((4-((3-hydroxypyrrolidin-1-yl)methyl)phenyl)ethynyl)phenyl)-3-isopropyl-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((4- (4- ((4- ((3-hydroxypyrrolidin-1-yl) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- ((3-hydroxypyrrolidin-1-yl) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one 32b (40 mg, 56.51. Mu. Mol) was added to 2mL of dichloromethane, boron trichloride (0.8 mL) was added and reacted at room temperature for 1 hour. After completion of the reaction, concentrated under reduced pressure, and the residue was purified by preparative liquid phase separation to give 5-hydroxy-6- ((4- (4- ((4- ((3-hydroxypyrrolidin-1-yl) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one 32 (9.78 mg,15.20 μmol,26.91% yieldd).
MS m/z(ESI)：528.0[M+1] +
Example 33
5-hydroxy-6-((4-(4-((4-(((3-hydroxycyclobutyl)amino)methyl)phenyl)ethynyl)phenyl)-3-isopropyl-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((4- (4- ((4- (((3-hydroxycyclobutyl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one
First step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-4-(4-((4-(((3-hydroxycyclobutyl)amino)methyl)phenyl)ethynyl)phenyl)-3-isopropylimidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (((3-hydroxycyclobutyl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one
24g (50 mg, 78.53. Mu. Mol) of 4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzaldehyde and 33a (19.41 mg, 157.05. Mu. Mol) of 3-aminocyclobutane-1-ol hydrochloride were dissolved in 1mL of 1, 2-dichloroethane, acetic acid (0.2 mL) was added, stirring was carried out for 30 minutes, and sodium triacetylborohydride (33.29 mg, 157.05. Mu. Mol) was added, and stirring was continued at room temperature for 12 hours. After completion of the reaction, 15mL of saturated aqueous sodium bicarbonate solution was added, quenched, dichloromethane (30 mL) and water (15 mL) were added, the aqueous phase was separated, the aqueous phase was extracted with dichloromethane (30 mL. Times.2), the combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was purified by preparative liquid chromatography (eluent: system B) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (((3-hydroxycyclobutyl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one 33B (20 mg, 28.25. Mu. Mol,35.98% yieldd).
MS m/z(ESI)：708.0[M+1] +
Second step
5-hydroxy-6-((4-(4-((4-(((3-hydroxycyclobutyl)amino)methyl)phenyl)ethynyl)phenyl)-3-isopropyl-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((4- (4- ((4- (((3-hydroxycyclobutyl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (((3-hydroxycyclobutyl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one 33b (20 mg, 28.25. Mu. Mol) was added to 2mL of dichloromethane, boron trichloride (0.8 mL) was added and reacted at room temperature for 1 hour. After completion of the reaction, concentrated under reduced pressure, and the residue was purified by preparative liquid phase separation to give 5-hydroxy-6- ((4- (4- ((4- (((3-hydroxycyclobutyl) amino) methyl) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one 33 (11 mg,17.08 μmol,60.45% yieldd).
MS m/z(ESI)：528.0[M+1] +
Example 34
1-(4-((4-(1-((5-hydroxy-6-oxo-1,6-dihydropyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)benzyl)azetidine-3-carbonitrile
1- (4- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) azetidine-3-carbonitrile
First step
1-(4-((4-(1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)benzyl)azetidine-3-carbonitrile
1- (4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) azetidine-3-carbonitrile
24g (43 mg, 67.53. Mu. Mol) of 4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzaldehyde and 34a (12.01 mg, 101.30. Mu. Mol) of azetidine-3-carbonitrile hydrochloride were dissolved in 1, 2-dichloroethane (999.73. Mu.L), acetic acid (4.06 mg, 67.53. Mu. Mol, 3.86. Mu.L) was added, stirred for 30 minutes, and sodium triacetylborohydride (28.63 mg, 135.06. Mu. Mol) was added and stirring was continued at room temperature for 12 hours. After completion of the reaction, 15mL of saturated aqueous sodium bicarbonate solution was added, quenched, dichloromethane (30 mL) and water (15 mL) were added, the solution was separated, the aqueous phase was extracted with dichloromethane (30 mL. Times.2), the combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the residue was purified by preparative liquid chromatography (eluent: system B) to give 1- (4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) azetidine-3-carbonitrile 34B (26 mg, 36.99. Mu. Mol,54.78% yieldd).
MS m/z(ESI)：703.3[M+1] +
Second step
1-(4-((4-(1-((5-hydroxy-6-oxo-1,6-dihydropyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)benzyl)azetidine-3-carbonitrile
1- (4- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) azetidine-3-carbonitrile
1- (4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) azetidine-3-carbonitrile 34b (26 mg, 36.99. Mu. Mol) was added to 2.5mL of dichloromethane, boron trichloride (0.1 mL) was added and reacted at room temperature for 1 hour. After completion of the reaction, quenched with methanol, concentrated under reduced pressure, and the residue was purified by preparative liquid phase separation to give 1- (4- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) azetidine-3-carbonitrile 34 (6.8 mg,10.62 μmol,28.70% yieldd).
MS m/z(ESI)：523.4[M+1] +
Example 35
1-(4-((4-(1-((5-hydroxy-6-oxo-1,6-dihydropyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)benzyl)pyrrolidine-3-carbonitrile
1- (4- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) pyrrolidine-3-carbonitrile
First step
1-(4-((4-(1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)benzyl)pyrrolidine-3-carbonitrile
1- (4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) pyrrolidine-3-carbonitrile
24g (40 mg, 62.82. Mu. Mol) of 4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzaldehyde and 35a (9.06 mg, 68.32. Mu. Mol) of pyrrolidine-3-carbonitrile hydrochloride were dissolved in 1mL of 1, 2-dichloroethane, acetic acid (3.77 mg, 62.82. Mu. Mol, 3.59. Mu.L) was added and stirred for 30 minutes, sodium triacetylborohydride (26.63 mg, 125.64. Mu. Mol) was added and stirring was continued at room temperature for 12 hours. After completion of the reaction, 15mL of saturated aqueous sodium bicarbonate solution was added, quenched, dichloromethane (30 mL) and water (15 mL) were added, the solution was separated, the aqueous phase was extracted with dichloromethane (30 mL. Times.2), the combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the residue was purified by preparative liquid chromatography (eluent: system B) to give 1- (4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) pyrrolidine-3-carbonitrile 35B (40 mg, 55.80. Mu. Mol,88.82% yieldd).
MS m/z(ESI)：717.4[M+1] +
Second step
1-(4-((4-(1-((5-hydroxy-6-oxo-1,6-dihydropyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)benzyl)pyrrolidine-3-carbonitrile
1- (4- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) pyrrolidine-3-carbonitrile
1- (4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) pyrrolidine-3-carbonitrile 35b (40 mg, 55.80. Mu. Mol) was added to 2mL of dichloromethane, boron trichloride (0.5 mL) was added and reacted at room temperature for 1 hour. After completion of the reaction, quenched with methanol, concentrated under reduced pressure, and the residue purified by preparative liquid phase separation to give 1- (4- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) pyrrolidine-3-carbonitrile 35 (8 mg,12.10 μmol,21.69% yieldd).
MS m/z(ESI)：537.0[M+1] +
Example 36
5-hydroxy-6-((3-isopropyl-4-(4-((4-((1-oxidothiomorpholino)methyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-4- (4- ((4- ((1-thiomorpholin oxide) methyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-isopropyl-4-(4-((4-((1-oxidothiomorpholino)methyl)phenyl)ethynyl)phenyl)imidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- ((1-thiomorpholin oxide) methyl) phenyl) ethynyl) phenyl) imidazolin-2-one
24g (40 mg, 62.82. Mu. Mol) of 4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzaldehyde and thiomorpholine 1-oxide 36a (14.67 mg, 94.23. Mu. Mol) were dissolved in 1ml of 1, 2-dichloroethane, acetic acid (3.77 mg, 62.82. Mu. Mol, 3.59. Mu.L) was added, stirred for 30 minutes, sodium triacetylborohydride (26.63 mg, 125.64. Mu. Mol) was added and stirring was continued at room temperature for 12 hours. After completion of the reaction, 15mL of saturated aqueous sodium bicarbonate solution was added, quenched, dichloromethane (30 mL) and water (15 mL) were added, the aqueous phase was separated, the aqueous phase was extracted with dichloromethane (30 mL. Times.2), the combined organic phases were washed with saturated aqueous sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the residue was purified by preparative liquid chromatography (eluent: system B) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- ((1-thiomorpholinomethyl) phenyl) ethynyl) phenyl) imidazolin-2-one 36B (20 mg, 27.03. Mu. Mol,43.03% yield).
MS m/z(ESI)：740.0[M+1] +
Second step
5-hydroxy-6-((3-isopropyl-4-(4-((4-((1-oxidothiomorpholino)methyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-4- (4- ((4- ((1-thiomorpholin oxide) methyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- ((1-thiomorpholino oxide) methyl) phenyl) ethynyl) phenyl) imidazolin-2-one 36b (20 mg, 27.03. Mu. Mol) was added to 2mL dichloromethane, boron trichloride (0.5 mL) was added and reacted at room temperature for 1 hour. After completion of the reaction, quenched with methanol, concentrated under reduced pressure, and the residue purified by preparative liquid phase separation to give 5-hydroxy-6- ((3-isopropyl-4- (4- ((4- ((1-thiomorpholin oxide methyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one 36 (4 mg,5.90 μmol,21.83% yieldd).
MS m/z(ESI)：560.0[M+1] +
According to the synthetic methods of examples 1-36, the following compounds were prepared, including:
example 88
1-((5-((4-(1-((5-hydroxy-6-oxo-1,6-dihydropyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)pyridin-2-yl)methyl)azetidine-3-carboxamide
1- ((5- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydroxypyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) pyridin-2-yl) methyl) azetidine-3-carboxamide
First step
1-(4-ethynylbenzyl)azetidine-3-carboxamide
1- (4-ethynylphenyl) azetidine-3-carboxamide
4-Acetylbenzaldehyde 88a (200 mg,1.54 mmol) and azetidine-3-carboxamide hydrochloride 88b (307.72 mg,2.25 mmol) were dissolved in 1, 2-dichloroethane (2.00 mL), acetic acid (92.28 mg,1.54mmol, 87.89. Mu.L) was added, stirred for 30 minutes, sodium triacetoxyborohydride (651.41 mg,3.07 mmol) was added, and stirring was continued at room temperature for 12 hours. After completion of the reaction, the reaction mixture was quenched by adding 15mL of saturated aqueous sodium hydrogencarbonate, dichloromethane (30 mL) and water (15 mL) in this order, the solution was separated, the aqueous phase was extracted with dichloromethane (30 mL. Times.2), the combined organic phases were washed with saturated aqueous sodium chloride (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated to dryness under reduced pressure, and the residue was purified by preparative liquid chromatography (eluent: system B) to give 1- (4-ethynylphenyl) azetidine-3-carboxamide 88c (100 mg, 466.72. Mu. Mol,30.37% yield).
MS m/z(ESI):214.9[M+1]
Second step
1-(4-((4-(1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)benzyl)azetidine-3-carboxamide
1- (4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) methyl) ethynyl) benzyl) azetidine-3-carboxamide
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -3-isopropylimidazolin-2-one 21e (50 mg, 78.80. Mu. Mol) and 1- (4-ethynylphenyl) azetidine-3-carboxamide 88c (33.77 mg, 157.60. Mu. Mol) in water (2 mL) was added bis triphenylphosphine palladium dichloride (2.21 mg, 3.15. Mu. Mol), tetrabutylammonium bromide (25.40 mg, 78.80. Mu. Mol) and piperidine (20.13 mg, 236.40. Mu. Mol) at room temperature. After the reaction was warmed to 70℃and stirred for 5 hours, the reaction mixture was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system B) to give 1- (4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) methyl) ethynyl) benzyl) azetidine-3-carboxamide 88d (30 mg, 41.62. Mu. Mol,52.81% yield).
MS m/z(ESI):721.0[M+1]
Third step
1-((5-((4-(1-((5-hydroxy-6-oxo-1,6-dihydropyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)pyridin-2-yl)methyl)azetidine-3-carboxamide
1- ((5- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydroxypyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) pyridin-2-yl) methyl) azetidine-3-carboxamide
1- (4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) methyl) ethynyl) benzyl) azetidine-3-carboxamide 88d (30 mg, 41.62. Mu. Mol) was added to 2mL of dichloromethane followed by boron trichloride (0.8 mL) and reacted at room temperature for 1 hour. After completion of the reaction, quenched with methanol, concentrated under reduced pressure, and the residue is further isolated and purified by preparation of a liquid phase to give 1- ((5- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydroxypyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazol-4-yl) phenyl) ethynyl) pyridin-2-yl) methyl) azetidine-3-carboxamide 88 (7 mg,9.88 μmol,23.75% yieldd).
MS m/z(ESI):541.3[M+1]
Example 89
5-hydroxy-6-((4-(4-((4-(2-hydroxyethoxy)phenyl)ethynyl)phenyl)-3-isopropyl-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((4- (4- ((4- (2-hydroxyethoxy) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
2-(4-((trimethylsilyl)ethynyl)phenoxy)ethan-1-ol
2- (4- ((trimethylsilyl) ethynyl) phenoxy) ethan-1-ol
To a solution of 2- (4-bromophenoxy) ethanol 89a (600 mg,2.76 mmol) and ethynyl (trimethyl) silane 89b (298.65 mg,3.04mmol, 429.71. Mu.L) in triethylamine (10.29 mL) were added copper iodide (52.64 mg, 276.42. Mu. Mol) and ditolylphosphine palladium dichloride (194.02 mg, 276.42. Mu. Mol) at room temperature. After stirring overnight at room temperature and completion of the reaction, the reaction mixture was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography (eluent: system B) to give 2- (4- ((trimethylsilyl) ethynyl) phenoxy) ethan-1-ol 89c (250 mg,1.07mmol,38.59% yieldd).
MS m/z(ESI):235.1[M+1]
Second step
2-(4-ethynylphenoxy)ethan-1-ol
2- (4-Acetylylphenoxy) ethan-1-ol
2- (4- ((trimethylsilyl) ethynyl) phenoxy) ethan-1-ol 89c (236 mg,1.01 mmol) was added to methanol, potassium carbonate (417.52 mg,3.02 mmol) was added and reacted at room temperature for 1 hour. After completion of the reaction, the reaction mixture was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: system A) to give 2- (4-ethynylphenoxy) ethan-1-ol 89d (120 mg, 739.90. Mu. Mol,73.48% yieldd).
MS m/z(ESI):163.0[M+1]
Third step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-4-(4-((4-(2-hydroxyethoxy)phenyl)ethynyl)phenyl)-3-isopropylimidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (2-hydroxyethyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -3-isopropylimidazolin-2-one 21e (60 mg, 94.56. Mu. Mol) 2- (4-ethynylphenoxy) ethan-1-ol 89d (30.67 mg, 189.12. Mu. Mol) in water (2 mL) was added bis triphenylphosphine palladium dichloride (2.65 mg, 3.78. Mu. Mol), tetrabutylammonium bromide (30.48 mg, 94.56. Mu. Mol) and piperidine (24.16 mg, 283.69. Mu. Mol) at room temperature. After the reaction was warmed to 70℃and stirred for 5 hours, the reaction was completed, the reaction solution was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (eluent: system B) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (2-hydroxyethyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one 89e (30 mg, 44.86. Mu. Mol,47.44% yieldd).
MS m/z(ESI):669.3[M+1]
Fourth step
5-hydroxy-6-((4-(4-((4-(2-hydroxyethoxy)phenyl)ethynyl)phenyl)-3-isopropyl-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((4- (4- ((4- (2-hydroxyethoxy) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4- ((4- (2-hydroxyethyl) phenyl) ethynyl) phenyl) -3-isopropylimidazolin-2-one 89e (30 mg, 44.86. Mu. Mol) was added to 2mL of dichloromethane, boron trichloride (0.5 mL) was added and reacted at room temperature for 1 hour. After completion of the reaction, quenched with methanol, concentrated under reduced pressure, and the residue was further isolated and purified by preparation of a liquid phase to give 5-hydroxy-6- ((4- (4- ((4- (2-hydroxyethoxy) phenyl) ethynyl) phenyl) -3-isopropyl-2-oxoimidazol-1-yl) methyl) pyrimidin-4 (3H) -one 89 (4 mg,6.48 μmol,14.44% yield).
MS m/z(ESI):488.9[M+1]
1 H NMR(400MHz,DMSO)δ12.60(s,1H),9.48(s,1H),7.79(s,1H),7.60–7.40(m,6H),6.99(d,J＝8.4Hz,2H),4.69(t,J＝8.2Hz,1H),4.26(d,J＝15.6Hz,1H),4.19(d,J＝15.6Hz,1H),4.02(t,J＝4.8Hz,2H),3.73–3.67(m,4H),3.04(t,J＝8.0Hz,1H),1.13(d,J＝6.8Hz,3H),0.77(d,J＝6.4Hz,3H).
Example 90
5-hydroxy-6-((3-isopropyl-4-(4-((4-(3-methoxyazetidine-1-carbonyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (3-methoxyazetidine-1-carbonyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
(4-ethynylphenyl)(3-methoxyazetidin-1-yl)methanone
(4-Acetylylphenyl) (3-methoxyazetidin-1-yl) methanone
4-Acetylylbenzoic acid 90a (500 mg,3.42 mmol) and 3-methoxyazacyclo-completed hydrochloride 90b (845.62 mg,6.84 mmol) were added to 5mL of methylene chloride, followed by 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (1.05 g,5.47 mmol), 4-dimethylaminopyridine (41.80 mg, 342.13. Mu. Mol) and reacted overnight at room temperature. The reaction solution was extracted with methylene chloride (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were successively washed with a saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was further separated and purified by silica gel column chromatography (eluent: system C) to give (4-ethynylphenyl) (3-methoxyazetidin-1-yl) methanone 90C (500 mg,2.32mmol,67.90% yield).
MS m/z(ESI)：216.2[M+1] +
Second step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-isopropyl-4-(4-((4-(3-methoxyazetidine-1-carbonyl)phenyl)ethynyl)phenyl)imidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- (3-methoxyazetidine-1-carbonyl) phenyl) ethynyl) phenyl) imidazolin-2-one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -3-isopropylimidazolin-2-one 21e (60 mg, 94.56. Mu. Mol) and (4-ethynylphenyl) (3-methoxyazetidin-1-yl) methanone 90c (40.71 mg, 189.12. Mu. Mol) in water (1.5 mL) was added, followed by stirring for 5 hours at 70℃with ditolylphosphine palladium dichloride (2.65 mg, 3.78. Mu. Mol), tetrabutylammonium bromide (30.48 mg, 94.56. Mu. Mol) and piperidine (24.16 mg, 283.69. Mu. Mol). The reaction solution was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was further separated and purified by silica gel column chromatography (eluent: system B) to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- (3-methoxyazetidine-1-carbonyl) phenyl) ethynyl) phenyl) imidazolin-2-one 90d (35 mg, 48.49. Mu. Mol,51.28% yieldd).
MS m/z(ESI)：722.0[M+1] +
Third step
5-hydroxy-6-((3-isopropyl-4-(4-((4-(3-methoxyazetidine-1-carbonyl)phenyl)ethynyl)phenyl)-2-o xoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (3-methoxyazetidine-1-carbonyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- (3-methoxyazetidine-1-carbonyl) phenyl) ethynyl) phenyl) imidazolin-2-one 90d (35 mg,48.49 μmol) was added to 2mL dichloromethane, boron trichloride (0.5 mL) was added and reacted at room temperature for 1 hour. After completion of the reaction, quenched with methanol, concentrated under reduced pressure, and the residue is further isolated and purified by preparation of a liquid phase to give 5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (3-methoxyazetidine-1-carbonyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one 90 (6 mg,8.40 μmol,17.33% yield).
MS m/z(ESI)：542.3[M+1] +
1 H NMR(400MHz,DMSO)δ12.59(br,1H),9.50(s,1H),7.79(s,1H),7.68(d,J＝8.3Hz,2H),7.61(d,J＝8.4Hz,2H),7.58(d,J＝8.4Hz,2H),7.52(d,J＝8.4Hz,2H),4.71(dd,J＝9.2,7.2Hz,1H),4.45(dt,J＝6.4,3.3Hz,1H),4.29–4.12(m,5H),3.85(q,J＝7.1Hz,1H),3.74-3.67(m,2H),3.22(s,3H),3.04(t,J＝8.0Hz,1H),1.13(d,J＝6.8Hz,3H),0.78(d,J＝6.8Hz,3H).
Example 91
5-hydroxy-6-((3-isopropyl-4-(4-((4-(1-oxidothiomorpholine-4-carbonyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (1-thiomorpholin-4-carbonyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
First step
(4-ethynylphenyl)(1-oxidothiomorpholino)methanone
(4-Acetylylphenyl) (1-thiomorpholine oxide) methanone
4-Acetylylbenzoic acid 90a (150 mg,1.03 mmol) and thiomorpholine 1-oxide hydrochloride 36a (255.61 mg,1.64 mmol) were added to 1mL of dichloromethane, followed by 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (314.82 mg,1.64 mmol) and 4-dimethylaminopyridine (12.54 mg, 102.64. Mu. Mol) and reacted overnight at room temperature. The reaction solution was extracted with methylene chloride (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with a saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was further separated and purified by silica gel column chromatography (eluent: system A) to give (4-ethynylphenyl) (1-thiomorpholine oxide) methanone 91a (100 mg, 404.35. Mu. Mol,39.39% yield).
MS m/z(ESI)：247.9[M+1] +
Second step
1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-isopropyl-4-(4-((4-(1-oxidothiomorpholine-4-carbonyl)phenyl)ethynyl)phenyl)imidazolidin-2-one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- (1-thiomorpholine-4-carbonyl) phenyl) ethynyl) phenyl) imidazolin-2-one
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -3-isopropylimidazolin-2-one 21e (50 mg, 78.80. Mu. Mol) and (4-ethynylphenyl) (1-thiomorpholine oxide) methanone 91a (38.98 mg, 157.60. Mu. Mol) in water (1.5 mL) at room temperature was added successively bis triphenylphosphine palladium dichloride (2.21 mg, 3.15. Mu. Mol), tetrabutylammonium bromide (25.40 mg, 78.80. Mu. Mol) and piperidine (20.13 mg, 236.40. Mu. Mol). The reaction was warmed to 70 ℃ and stirred for 5 hours. The reaction solution was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography to give 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- (1-thiomorpholine-4-carbonyl) phenyl) ethynyl) phenyl) imidazolin-2-one 91B (30 mg, 39.79. Mu. Mol,50.50% yield).
MS m/z(ESI)：754.9[M+1] +
Third step
5-hydroxy-6-((3-isopropyl-4-(4-((4-(1-oxidothiomorpholine-4-carbonyl)phenyl)ethynyl)phenyl)-2-oxoimidazolidin-1-yl)methyl)pyrimidin-4(3H)-one
5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (1-thiomorpholin-4-carbonyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one
1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-4- (4- ((4- (1-thiomorpholine-4-carbonyl) phenyl) ethynyl) phenyl) imidazolin-2-one 91b (30 mg, 39.79. Mu. Mol) was added to 2mL dichloromethane, boron trichloride (0.8 mL) was added and reacted at room temperature for 1 hour. After completion of the reaction, quenched with methanol, concentrated under reduced pressure, and the residue is further isolated and purified by preparation of a liquid phase to give 5-hydroxy-6- ((3-isopropyl-4- (4- ((4- (1-thiomorpholine-4-carbonyl) phenyl) ethynyl) phenyl) -2-oxoimidazolin-1-yl) methyl) pyrimidin-4 (3H) -one 91 (8 mg,11.57 μmol,29.08% yield).
MS m/z(ESI)：574.2[M+1] +
Example 92
2-hydroxy-N-(4-((4-(1-((5-hydroxy-6-oxo-1,6-dihydropyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)benzyl)acetamide
2-hydroxy-N- (4- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) acetamide
First step
N-(4-ethynylbenzyl)-2-hydroxyacetamide
N- (4-ethynylbenzyl) -2-hydroxyacetamide
(4-Acetylylphenyl) methylamine 92a (600 mg,3.58mmol, S02) and 2-glycolic acid 92b (326.64 mg,4.30 mmol) were added to 2mL of methylene chloride, followed by 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (1.10 g,5.73 mmol), 4-dimethylaminopyridine (43.73 mg, 357.92. Mu. Mol) and reacted overnight at room temperature. After completion of the reaction, the reaction mixture was extracted with methylene chloride (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with a saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography to give N- (4-ethynylbenzyl) -2-hydroxyacetamide 92C (300 mg,1.59mmol,44.30% yieldd).
MS m/z(ESI)：190.2[M+1] +
Second step
N-(4-((4-(1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)benzyl)-2-hydroxyacetamide
N- (4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) -2-hydroxyacetamide
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -3-isopropylimidazolin-2-one 21e (60 mg, 94.56. Mu. Mol) and N- (4-ethynylbenzyl) -2-hydroxyacetamide 92c (35.78 mg, 189.12. Mu. Mol) in water (1 mL) at room temperature was added bis triphenylphosphine palladium dichloride (2.65 mg, 3.78. Mu. Mol), tetrabutylammonium bromide (30.48 mg, 94.56. Mu. Mol) and piperidine (24.16 mg, 283.69. Mu. Mol) in this order, and the reaction was warmed to 70℃and stirred for 5 hours. The reaction solution was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure, and the resulting residue was purified by silica gel column chromatography to give N- (4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) -2-hydroxyacetamide 92d (30 mg, 43.12. Mu. Mol,45.60% yieldd).
MS m/z(ESI)：696.3[M+1] +
Third step
2-hydroxy-N-(4-((4-(1-((5-hydroxy-6-oxo-1,6-dihydropyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)benzyl)acetamide
2-hydroxy-N- (4- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) acetamide
N- (4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) -2-hydroxyacetamide 92d (20 mg, 28.74. Mu. Mol) was added to 1.5mL of dichloromethane, boron trichloride (0.8 mL) was added, and the mixture was reacted at room temperature for 1 hour. After completion of the reaction, quenched with methanol, concentrated under reduced pressure, and the residue is further separated and purified by preparative liquid phase to give 2-hydroxy-N- (4- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) benzyl) acetamide 92 (8 mg,12.03 μmol,41.86% yieldd).
MS m/z(ESI)：516.0[M+1] +
1 H NMR(400MHz,DMSO)δ12.57(br,1H),9.48(s,1H),8.37(t,J＝6.4Hz,1H),7.79(s,1H),7.59–7.45(m,6H),7.31(d,J＝8.4Hz,2H),4.70(dd,J＝9.2,7.2Hz,1H),4.33(d,J＝6.3Hz,2H),4.26(d,J＝15.6Hz,1H),4.18(d,J＝15.6Hz,1H),3.87(s,2H),3.74-3.67(m,4H),3.04(t,J＝8.0Hz,1H),1.13(d,J＝6.8Hz,3H),0.77(d,J＝6.8Hz,3H).
Example 93
4-((4-(1-((5-hydroxy-6-oxo-1,6-dihydropyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)-N-(2-methoxyethyl)benzamide
4- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) -N- (2-methoxyethyl) benzamide
First step
4-ethynyl-N-(2-methoxyethyl)benzamide
4-ethynyl-N- (2-methoxyethyl) benzamide
4-Acetylylbenzoic acid 90a (500 mg,3.42 mmol) and methoxyethylamine 93a (513.95 mg,6.84 mmol) were added to 2mL of methylene chloride, and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (655.87 mg,3.42 mmol) and 4-dimethylaminopyridine (41.80 mg, 342.13. Mu. Mol) were added in this order and reacted overnight at room temperature. The reaction solution was extracted with dichloromethane (30 ml×2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 ml×2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the resulting residue was further separated and purified by silica gel column chromatography (eluent: system A) was purified to give 4-ethynyl-N- (2-methoxyethyl) benzamide 93b (360 mg,1.77mmol,51.77% yield).
MS m/z(ESI)：204.2[M+1] +
Second step
4-((4-(1-((5,6-bis(benzyloxy)pyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)-N-(2-methoxyethyl)benzamide
4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) -N- (2-methoxyethyl) benzamide
To a solution of 1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -4- (4-iodophenyl) -3-isopropylimidazolin-2-one 21e (60 mg, 94.56. Mu. Mol) and 4-ethynyl-N- (2-methoxyethyl) benzamide 93b (38.44 mg, 189.12. Mu. Mol) in water (1 mL) at room temperature was added bis triphenylphosphine palladium dichloride (2.65 mg, 3.78. Mu. Mol), tetrabutylammonium bromide (30.48 mg, 94.56. Mu. Mol) and piperidine (24.16 mg, 283.69. Mu. Mol) in this order, and the reaction was warmed to 70℃and stirred for 5 hours. The reaction solution was extracted with ethyl acetate (30 mL. Times.2), the aqueous layer was separated, the combined organic phases were washed successively with saturated sodium chloride solution (30 mL. Times.2), dried over anhydrous sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (eluent: system B) to give 4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) -N- (2-methoxyethyl) benzamide 93d (40 mg, 56.35. Mu. Mol,59.59% yieldd).
MS m/z(ESI)：710.3[M+1] +
Third step
4-((4-(1-((5-hydroxy-6-oxo-1,6-dihydropyrimidin-4-yl)methyl)-3-isopropyl-2-oxoimidazolidin-4-yl)phenyl)ethynyl)-N-(2-methoxyethyl)benzamide
4- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) -N- (2-methoxyethyl) benzamide
4- ((4- (1- ((5, 6-bis (benzyloxy) pyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) -N- (2-methoxyethyl) benzamide 93d (40 mg,56.35 μmol) was added to 2mL dichloromethane, boron trichloride (0.8 mL) was added and reacted at room temperature for 1 hour. After completion of the reaction, quenched with methanol, concentrated under reduced pressure, and the residue is further isolated and purified by preparation of a liquid phase to give 4- ((4- (1- ((5-hydroxy-6-oxo-1, 6-dihydropyrimidin-4-yl) methyl) -3-isopropyl-2-oxoimidazolin-4-yl) phenyl) ethynyl) -N- (2-methoxyethyl) benzamide 93 (1.82 mg,2.68 μmol,4.75% yield).
MS m/z(ESI)：530.2[M+1] +
1H NMR(400MHz,DMSO)δ9.61(br,1H),8.65(s,1H),7.92-7.89(m,3H),7.64(d,J＝8.0,2H),7.58(d,J＝8.0Hz,2H),7.52(d,J＝8.0Hz,2H),4.71(t,J＝8.0,1H),4.24(d,J＝15.6Hz,,1H),4.22(d,J＝15.6Hz,,1H),3.72-3.67(m,2H),3.47–3.42(m,4H),3.27(s,3H),3.05(t,J＝8.0Hz,1H),1.13(d,J＝6.8Hz,3H),0.78(d,J＝6.4Hz,3H).
According to the synthetic methods of examples 1-93, the following compounds were prepared, including:
biological evaluation
Test example 1 inhibition assay of LpxC enzymatic Activity by Compounds of the invention
The following methods were used to determine the extent of inhibition of the enzymatic activity of the compounds of the invention on recombinant Pseudomonas aeruginosa LpxC under in vitro conditions.
The experimental procedure is briefly described as follows: test compounds were first dissolved in DMSO to prepare 10mM stock solutions. Reactions were performed in 96-well microplates, first 20 μl of recombinant Pseudomonas aeruginosa LpxC (available from Signalway Antibody under the trade designation AP 74647-2) was added to the wells at a final concentration of 5nM, respectively; adding 5 mu L of a compound to be tested, diluting the compound 4 times, and 8 concentration points, wherein the concentration range is 0.61-10000nM; mu.L of the LpxC substrate UDP-3-O- (R-3-hydroxydecanoyl) -GlcNAc (available from Biosynth Carbosynth under the trade name mu 75071) was added thereto at a final substrate concentration of 10. Mu.M and incubated at 25℃for 120 minutes. Then 20. Mu.L of 2.0mg/mL fluoroscamine (purchased from Sigma-Aldrich under the trade name F9015 and 1:1 dimethylformamide/acetonite) was added to the reaction system, and the mixture was stirred and reacted for 10 minutes; finally, 50. Mu.L of 200mM sodium phosphate buffer was added (pH 8.0) the reaction was stopped and read using a microplate reader (BMG) with excitation and emission wavelengths of 390nm and 495nm, respectively. The percent inhibition of the compounds at each concentration was calculated by comparison with the fluorescence intensity ratio of the control group (0.1% dmso) and nonlinear regression analysis was performed on the compound concentration vs. inhibition by GraphPad Prism 5 software to obtain IC of the compounds 50 The values are shown in Table 1 below.
TABLE 1 inhibition of LpxC enzymatic Activity by Compounds of the invention
Numbering of compounds IC 50 /nM
Example 7 42.45
Example 9 13.12
Example 10 22.99
Example 11 8.00
Example 13 15.72
Example 15 33.17
Example 16 24.69
Example 17 23.17
Example 22 36.1
Example 23 32.08
Example 24 20.58
Example 25 28.88
Example 26 9.55
Example 27 15.84
Example 28 35.53
Example 31 37.4
Example 36 52.02
Example 88 14.92
Example 90 19.99
Example 92 55.43
Example 93 60.9
Conclusion: IC with recombinant Pseudomonas aeruginosa LpxC enzyme activity inhibition by the compounds of the invention 50 All are less than 100nM, and have remarkable inhibition effect on LpxC enzyme activity.
Test example 2 evaluation of antibacterial Activity of the Compounds of the invention
In vitro minimum inhibitory concentration (minimum inhibitory concentration, MIC) assays were performed according to the guidelines of CLSI, using a mini broth dilution method.
The experimental procedure is briefly described as follows: test compounds were dissolved in DMSO to prepare 12.8mg/mL stock solution, and then 11 double dilutions of 100 Xhigh concentration working solution (final system concentration of 64. Mu.g/mL-0.06. Mu.g/mL) were prepared using DMSO. The strain frozen by glycerol at-80 deg.C (K.Pneumoniae ATCC13883 and E.coli ATCC 25922) is connected to a solid agar culture medium, placed in an incubator at 35 deg.C for culturing for 18-24 h to finish the preparation of the strain, then a proper amount of solid flat culture is collected and resuspended in physiological saline, and the mixture is uniformly mixed, and the turbidity of the bacterial suspension is regulated to a proper turbidity by a turbidity meter to be about 1X 10 8 cfu/mL bacteria, and then diluting the turbidity-adjusted bacterial suspension with a test medium to a bacterial concentration of 5×10 5 cfu/ml, the inoculum preparation is completed. Inoculating 198. Mu.L of the inoculating solution into a 96-well plate, adding 2. Mu.L of 100 Xhigh-concentration working solution of the compound, culturing the 96-well plate at 35 ℃ for 18-24 h, and observing the test plate by naked eyes after culturingThe long minimum drug concentration is the Minimum Inhibitory Concentration (MIC) of the compound, as specified in table 2 below.
TABLE 2 antibacterial Activity test results of the inventive Compounds
Conclusion: the compound has better inhibition effect on both pneumobacillus (K.Pneumoniae ATCC 13883) and escherichia coli (E.coli ATCC 25922).
Remarks: ND represents not measured.
Test example 3 ICR mouse pharmacokinetic study of the Compound of the invention
1. Purpose of experiment
The ICR mice are taken as test animals, the LC/MS/MS method is adopted to determine the intravenous injection or the intragastric administration of the compound 13 of the invention, the drug concentration in plasma at different times is determined, and the pharmacokinetic characteristics of the compound of the invention in the mice are studied.
2. Experimental protocol
2.1 experimental drugs and animals;
the compound of example 13;
ICR mice, male, 29.0-33.8 g, purchased from Peking Vitre Liwa laboratory animal technologies Co.
2.2 pharmaceutical formulation
Intravenous injection group: weighing a proper amount of medicine, adding 10% HP-beta-CD water solution, vortex and ultrasonic for 60 min. Adding 10 μl of 1M HCl, vortexing, mixing, and filtering with (Rephile, nylon,0.45 μm) pH 3.5-4.0 to obtain colorless solution, and preparing final concentration of 0.2mg/mL;
oral gavage group: weighing a proper amount of medicine, adding 10% Solutol HS15-20% HP-beta-CD, vortexing, and performing ultrasonic treatment for 30 minutes to obtain a colorless solution, and preparing the final preparation concentration of 0.5mg/kg.
2.3 administration of drugs
ICR mice, each test compound was divided into intravenous (9 per group) and intragastric (9 per group), and fed by orbital intravenous (1 mg/kg dose, 5mL/kg dose volume) and intragastric (5 mg/kg dose, 10mL/kg dose volume) administration after overnight fast, respectively, 4 hours after administration.
3. Operation of
About 0.1mL of blood was collected via the cervical orbit before and after 0.083 hours, 0.25 hours, 0.5 hours, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours and 24 hours, and whole blood samples were placed in an anticoagulant tube containing EDTA-K2. After blood sample collection, the plasma was centrifuged (centrifugation conditions: 1500g,10 min). The collected plasma was stored at-40 to-20℃prior to analysis.
The LC-MS/MS was used to determine the amount of test compound in the plasma of mice following intravenous and intragastric administration of the different compounds.
4. Pharmacokinetic parameter results
The pharmacokinetic parameters of the compounds of the invention are shown in table 3.
TABLE 3 pharmacokinetic parameter results for the compounds of the invention
Conclusion: the compound of the embodiment 13 of the invention has higher blood concentration and area under the curve, higher bioavailability and better pharmacokinetic property.

Claims (14)

  1. A compound of formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof:
    wherein:
    x and Y are each independently selected from C or N, and X, Y are not both N;
    ring a is selected from 4-to 6-membered heteroaryl or 4-to 6-membered heterocyclyl, preferably 5-membered heteroaryl or 5-membered heterocyclyl;
    L 1 selected from single bonds or-CH 2 -；
    R 1 Identical or different, each independently selected from-G 1 -R 4 ；
    G 1 Selected from single bond, -CH 2 -or-C (=o) -;
    R 2 the same or different, each independently selected from hydroxy, cyano, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally further substituted with one or more halogen, hydroxy, cyano, or alkoxy substituents;
    R 3 identical or different, each independently selected from hydroxy, cyano, halogen, alkyl, cycloalkyl, heterocyclyl, alkoxy or-C (O) R 5 Wherein said alkyl, cycloalkyl, heterocyclyl OR alkoxy is optionally further substituted with one OR more groups selected from halogen, hydroxy, cyano, alkoxy, -C (O) OR 5 or-C (O) NR 6 R 7 Is substituted by a substituent of (2);
    R 4 selected from cyano, halogen, alkyl, hydroxy, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C (O) R 5 、-C(O)OR 5 、-OC(O)R 5 、-NR 6 R 7 、-C(O)NR 6 R 7 、-SO 2 NR 6 R 7 or-NR 6 C(O)R 7 Wherein said alkoxy, alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted with one or more R A Substituted;
    R A selected from halogen, hydroxy, amino, hydroxyalkyl, alkoxy, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C (O) R 5 、-C(O)OR 5 、-OC(O)R 5 、-NR 6 R 7 、-C(O)NR 6 R 7 、-SO 2 NR 6 R 7 or-NR 6 C(O)R 7 Wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally further substituted with one or more substituents selected from halogen, hydroxy, amino, haloalkyl, hydroxyalkyl, alkoxy, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, -C (O) R 5 、-C(O)OR 5 、-OC(O)R 5 、-NR 6 R 7 、-C(O)NR 6 R 7 、-SO 2 NR 6 R 7 or-NR 6 C(O)R 7 Is substituted by a substituent of (a);
    R 5 selected from a hydrogen atom, an alkyl group, a cycloalkyl group, a heterocyclic group, an aryl group or a heteroaryl group, wherein the alkyl group, the cycloalkyl group, the heterocyclic group, the aryl group or the heteroaryl group is optionally further substituted with one or more groups selected from a hydroxyl group, a halogen group, a nitro group, a cyano group, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, a cycloalkyl group, a heterocyclic group, an aryl group, a heteroaryl group, =o, -C (O) R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO 2 NR 9 R 10 or-NR 9 C(O)R 10 Is substituted by a substituent of (2);
    R 6 and R is 7 Each independently selected from a hydrogen atom, hydroxy, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl, wherein said alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl or heteroaryl is optionally further substituted with one or more groups selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =o, -C (O) R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO 2 NR 9 R 10 or-NR 9 C(O)R 10 Is substituted by a substituent of (2);
    Alternatively, R 6 And R is 7 Together with the atoms to which they are attached form a 4-8 membered heterocyclic group, where the 4-8 membered heterocyclic group contains one or more N, O, S or SO 2 And said 4-8 membered heterocyclyl is optionally further substituted with one or more substituents selected from hydroxy, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, =o, -C (O) R 8 、-C(O)OR 8 、-OC(O)R 8 、-NR 9 R 10 、-C(O)NR 9 R 10 、-SO 2 NR 9 R 10 or-NR 9 C(O)R 10 Is substituted by a substituent of (2);
    R 8 、R 9 and R is 10 Each independently selected from the group consisting of hydrogen, alkyl, amino, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally further substituted with one or more substituents selected from the group consisting of hydroxy, halogen, nitro, amino, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxyl, or carboxylate;
    m is 0,1,2 or 3;
    n is 0,1 or 2; n is preferably 0; and is also provided with
    p is 0,1 or 2.
  2. The compound of claim 1, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, which is a compound of formula (II):
    wherein: ring A, R 1 ～R 3 、L 1 The definitions of m, n and p are as defined in claim 1.
  3. A compound according to claim 2, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, which is a compound of formula (III):
    wherein:
    R A selected from the group consisting of haloalkyl, hydroxyalkyl, alkoxy, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxyl, wherein said alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally further substituted with a substituent of carboxyl;
    q is 0,1 or 2;
    ring A, G 1 、R 2 、R 3 、L 1 The definitions of n and p are as defined in claim 1.
  4. A compound according to any one of claims 1 to 3, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein ring a is selected from:
  5. a compound according to any one of claims 1 to 3, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
    Selected from:
  6. a compound according to any one of claims 1 to 2, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein
    Selected from:
  7. a compound according to any one of claims 1 to 3, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein n is selected from 0.
  8. A compound according to any one of claims 1 to 3, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein L 1 Selected from-CH 2 -。
  9. A compound according to any one of claims 1 to 8, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein the compound is:
  10. a process for the preparation of a compound of formula (I) or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, which process comprises:
    coupling the compound of the general formula (I-a) with the compound of the general formula (I-b) under the action of a catalyst, and optionally removing the protecting group to obtain the compound of the general formula (I);
    wherein:
    X 1 selected from halogen;
    ring A, X, Y, R 1 ～R 3 、L 1 The definitions of n, m and p are as defined in claim 1.
  11. A pharmaceutical composition comprising an effective amount of a compound according to any one of claims 1 to 9, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, excipient, or combination thereof.
  12. Use of a compound according to any one of claims 1 to 9, or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 11, for the preparation of an LPXC inhibitor.
  13. Use of a compound according to any one of claims 1 to 9, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 11, for the manufacture of a medicament for the treatment of a disease mediated by LPXC, wherein the disease mediated by LPXC is selected from bacterial infections caused by gram-negative bacteria.
  14. The use according to claim 13, wherein the gram-negative bacteria are selected from the group consisting of escherichia coli, pseudomonas aeruginosa, proteus, shigella dysenteriae, pneumobacillus, bacillus brucellosis, typhoid bacillus, acinetobacter, yersinia, legionella pneumophila, bordetella pertussis, shigella, pasteur, vibrio cholerae, neisseria meningitidis.
CN202280052824.6A 2021-08-05 2022-08-04 Aromatic acetylene derivative and preparation method and application thereof Pending CN117751113A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
CN2021108937563 2021-08-05
CN202110893756 2021-08-05
CN202210596714 2022-05-30
CN2022105967148 2022-05-30
CN2022107562273 2022-06-29
CN202210756227 2022-06-29
PCT/CN2022/110172 WO2023011573A1 (en) 2021-08-05 2022-08-04 Aromatic acetylene derivative, preparation method therefor, and use thereof

Publications (1)

Publication Number Publication Date
CN117751113A true CN117751113A (en) 2024-03-22

Family

ID=85155288

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280052824.6A Pending CN117751113A (en) 2021-08-05 2022-08-04 Aromatic acetylene derivative and preparation method and application thereof

Country Status (2)

Country Link
CN (1) CN117751113A (en)
WO (1) WO2023011573A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024083177A1 (en) * 2022-10-21 2024-04-25 浙江海正药业股份有限公司 Aromatic acetylene derivative, preparation method therefor and medical use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1957449A1 (en) * 2005-12-01 2008-08-20 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
CN101528711A (en) * 2006-08-31 2009-09-09 先灵公司 Hydantoin derivatives useful as antibacterial agents
CN101765585B (en) * 2007-06-12 2017-03-15 尔察祯有限公司 Antiseptic
AU2009279949A1 (en) * 2008-08-04 2010-02-11 Merck Sharp & Dohme Corp. Urea derivatives as antibacterial agents
WO2010100475A1 (en) * 2009-03-02 2010-09-10 Astrazeneca Ab Hydroxamic acid derivatives as gram-negative antibacterial agents
ES2909122T3 (en) * 2015-11-09 2022-05-05 Forge Therapeutics Inc Compounds based on hydroxypyridinone and hydroxypyrimidinone for the treatment of bacterial infections
WO2020061375A1 (en) * 2018-09-20 2020-03-26 Forge Therapeutics, Inc. Antibacterial compounds
US20220081421A1 (en) * 2018-11-14 2022-03-17 Forge Therapeutics, Inc. Antibacterial compounds

Also Published As

Publication number Publication date
WO2023011573A1 (en) 2023-02-09

Similar Documents

Publication Publication Date Title
JP5651692B2 (en) Condensed aminodihydro-oxazine derivatives
US20180362543A1 (en) Hiv replication inhibitor
AU2008341352B2 (en) Dipeptidyl peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
KR20080046728A (en) Heterocyclic compound, and production process and use thereof
JP7044801B2 (en) CDK4 / 6 inhibitor
US20160031907A1 (en) Substituted Benzene Compounds
US11897899B2 (en) Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
JP6601818B2 (en) Polyene macrolide derivatives
JPWO2017006953A1 (en) Heterocyclic derivatives having TrkA inhibitory activity
JPWO2017135399A1 (en) Nitrogen-containing heterocyclic and carbocyclic derivatives having TrkA inhibitory activity
JP2010531868A (en) 3-Spiropyrimidinetrione-quinoline derivatives and their use as antibacterial agents
WO2015147247A1 (en) Tricyclic derivative having hiv replication inhibitory activity
WO2019093450A1 (en) Diazabicyclooctane derivative
CN117751113A (en) Aromatic acetylene derivative and preparation method and application thereof
CN107614498B (en) Diaza-benzofluoranthenes
AU2017323112B2 (en) Pyrido five-element aromatic ring compound, preparation method therefor and use thereof
CN117769548A (en) Aromatic acetylene derivative and preparation method and application thereof
CN116390923A (en) Heterocyclic derivative and preparation method and application thereof
JP7250405B2 (en) Cyclic compound having dopamine D3 receptor antagonistic activity
JP6692113B2 (en) Pharmaceutical composition containing 6-membered heterocyclic derivative
JP2024519496A (en) Compounds for targeting the degradation of Bruton's tyrosine kinase - Patent Application 20070229633
WO2022152852A1 (en) Antagonists of mrgx2
CN117730080A (en) Pyridopyrimidinone derivative and preparation method and application thereof
CN117534665A (en) Diacylglycerol kinase inhibitors
TW202309039A (en) Compounds for targeting degradation of bruton's tyrosine kinase

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination